<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Nutr.</journal-id>
<journal-title>Frontiers in Nutrition</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Nutr.</abbrev-journal-title>
<issn pub-type="epub">2296-861X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fnut.2024.1408804</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Nutrition</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Beet supplementation mitigates post-exercise inflammation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><name><surname>Nieman</surname> <given-names>David C.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/210374/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Sakaguchi</surname> <given-names>Camila A.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Williams</surname> <given-names>James C.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Mulani</surname> <given-names>Fayaj A.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Shivprasad Suresh</surname> <given-names>Patil</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2205223/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Omar</surname> <given-names>Ashraf M.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author"><name><surname>Zhang</surname> <given-names>Qibin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Human Performance Laboratory, Appalachian State University, North Carolina Research Campus</institution>, <addr-line>Kannapolis, NC</addr-line>, <country>United States</country></aff>
<aff id="aff2"><sup>2</sup><institution>UNCG Center for Translational Biomedical Research, University of North Carolina at Greensboro, North Carolina Research Campus</institution>, <addr-line>Kannapolis, NC</addr-line>, <country>United States</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0002">
<p>Edited by: Alvaro L&#x00F3;pez Samanes, Comillas Pontifical University, Spain</p>
</fn>
<fn fn-type="edited-by" id="fn0003">
<p>Reviewed by: Jonathan Peake, Queensland University of Technology, Australia</p>
<p>Diego Fern&#x00E1;ndez L&#x00E1;zaro, University of Valladolid, Spain</p>
<p>Tzortzis Nomikos, Harokopio University, Greece</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: David C. Nieman, <email>niemandc@appstate.edu</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>05</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>11</volume>
<elocation-id>1408804</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>03</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>05</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2024 Nieman, Sakaguchi, Williams, Mulani, Shivprasad Suresh, Omar and Zhang.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Nieman, Sakaguchi, Williams, Mulani, Shivprasad Suresh, Omar and Zhang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec id="sec1">
<title>Objectives</title>
<p>This study investigated the efficacy of a mixed beet-based supplement (BEET) versus placebo (PL) in countering inflammation during recovery from 2.25&#x2009;h of intensive cycling in 20 male and female cyclists. A multi-omics approach was used that included untargeted proteomics and a targeted oxylipin panel.</p>
</sec>
<sec id="sec2">
<title>Methods</title>
<p>A randomized, placebo-controlled, double-blind, crossover design was used with two 2-week supplementation periods and a 2-week washout period. Supplementation periods were followed by a 2.25&#x2009;h cycling bout at close to 70%VO<sub>2max</sub>. The BEET supplement provided 212&#x2009;mg of nitrates per day, 200&#x2009;mg caffeine from green tea extract, 44&#x2009;mg vitamin C from Camu Camu berry, B-vitamins from quinoa sprouts (40% Daily Value for thiamin, riboflavin, niacin, and vitamin B6), and 2.5&#x2009;g of a mushroom blend containing Cordyceps sinensis and Inonotus obliquus. Six blood samples were collected before and after supplementation (overnight fasted state), immediately post-exercise, and at 1.5&#x2009;h-, 3&#x2009;h-, and 24&#x2009;h-post-exercise.</p>
</sec>
<sec id="sec3">
<title>Results</title>
<p>The 2.25&#x2009;h cycling bout increased plasma levels of 41 of 67 oxylipins detected. BEET supplementation significantly increased plasma nitrate (NO<sub>3</sub><sup>&#x2212;</sup>) and nitrite (NO<sub>2</sub><sup>&#x2212;</sup>) (sum, NO<sub>3</sub><sup>&#x2212;</sup>&#x2009;+&#x2009;NO<sub>2</sub><sup>&#x2212;</sup>) concentrations (interaction effect, <italic>p</italic>&#x2009;&#x003C;&#x2009;0.001) and two anti-inflammatory oxylipins [18-hydroxyeicosapentaenoic acid (18-HEPE) and 4-hydroxy-docosahexanoic acid (4-HDoHE)]. The untargeted proteomics analysis identified 616 proteins (458 across all times points), and 2-way ANOVA revealed a cluster of 45 proteins that were decreased and a cluster of 21 that were increased in the BEET versus PL trials. Functional enrichment supported significant BEET-related reductions in inflammation-related proteins including several proteins related to complement activation, the acute phase response, and immune cell adhesion, migration, and differentiation.</p>
</sec>
<sec id="sec4">
<title>Discussion</title>
<p>Intake of a BEET-based supplement during a 2-week period was linked to higher plasma levels of NO<sub>3</sub><sup>&#x2212;</sup>&#x2009;+&#x2009;NO<sub>2</sub><sup>&#x2212;</sup>, elevated post-exercise levels of two anti-inflammatory oxylipins, and a significant decrease in a cluster of proteins involved in complement activation and inflammation. These data support that 2-weeks intake of nitrate from a mixed beet-based supplement moderated protein biomarkers of exercise-induced inflammation in athletes.</p>
</sec>
</abstract>
<kwd-group>
<kwd>beets</kwd>
<kwd>exercise</kwd>
<kwd>proteomics</kwd>
<kwd>oxylipins</kwd>
<kwd>inflammation</kwd>
</kwd-group>
<counts>
<fig-count count="5"/>
<table-count count="5"/>
<equation-count count="0"/>
<ref-count count="55"/>
<page-count count="13"/>
<word-count count="8585"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Sport and Exercise Nutrition</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec5">
<title>Introduction</title>
<p>Nitrate is found in some root vegetables such as beets and in green leafy vegetables such as spinach and lettuce. The typical Western diet provides about 110&#x2009;mg/day nitrate (<xref ref-type="bibr" rid="ref1">1</xref>, <xref ref-type="bibr" rid="ref2">2</xref>). After ingestion, nitrate is metabolized to nitric oxide and other bioactive nitrogen oxides through a complex pathway. Nitrate is absorbed in the small intestine and peak plasma levels can be measured 30&#x2013;60&#x2009;min post-intake with an effective half-life of about six hours (<xref ref-type="bibr" rid="ref3">3</xref>). Nitrate is cleared by the kidneys, but about 25% of the nitrate is taken up and secreted by the salivary glands and is subsequently reduced to nitrite by commensal bacteria in the mouth (<xref ref-type="bibr" rid="ref4">4</xref>). The nitrite is then swallowed, absorbed through the intestinal tract, and further reduced to nitric oxide and other nitrite intermediates by enzymatic and nonenzymatic mechanisms in the blood and tissues. The use of mouthwashes, antacids, and chewing gum can interfere with the microbiome in the mouth and the conversion of nitrate to nitrite.</p>
<p>Dietary nitrate has been linked to several health-related benefits including blood pressure reduction, improved vascular function, and modulation of inflammatory processes and immune cell function (<xref ref-type="bibr" rid="ref3">3</xref>). Nitric oxide acts as a signaling molecule during exercise and has physiological effects including vasodilation to increase blood flow regulation of muscle contraction and glucose uptake regulation of cellular respiration. The primary performance benefit of nitrate supplementation appears to be a reduction in the energy cost of exercise and a corresponding modest improvement in endurance capacity (<xref ref-type="bibr" rid="ref5 ref6 ref7">5&#x2013;7</xref>). Studies reporting performance benefits used acute nitrate doses of 5&#x2013;6&#x2009;mmol (or about 300&#x2009;mg), or chronic doses at about half that amount (<xref ref-type="bibr" rid="ref8">8</xref>). Chronic nitrate supplementation has not been consistently linked to improvements in aerobic capacity or performance (<xref ref-type="bibr" rid="ref9">9</xref>). Concerns have been raised about high nitrate intake by athletes and the formation of carcinogenic N-nitroso compounds, a process that may be inhibited by vitamin C (<xref ref-type="bibr" rid="ref10 ref11 ref12 ref13">10&#x2013;13</xref>). An acceptable daily intake (ADI) level of 3.7&#x2009;mg nitrates per kg body weight has been recommended by the Joint FAO/WHO Expert Committee on Food Additives (JECFA) (<xref ref-type="bibr" rid="ref14">14</xref>). This recommendation includes all nitrate sources including plant foods, drinking water, and cured and processed meats, although a different approach is recommended for nitrate from plant food sources (<xref ref-type="bibr" rid="ref15">15</xref>). Co-supplementation of nitrate with caffeine, vitamin C, and other food components may enhance potential beneficial effects from moderate intake of nitrate and minimize risks from N-nitroso compounds (<xref ref-type="bibr" rid="ref16">16</xref>).</p>
<p>Nitric oxide is considered a potent anti-inflammatory mediator and inhibitor of leukocyte recruitment, a key feature of inflammatory responses (<xref ref-type="bibr" rid="ref3">3</xref>). However, most of the evidence comes from rodent-based studies. Human studies investigating the effects of nitrate or nitrate-rich beetroot juice on exercise-induced inflammation and muscle damage have produced mixed results (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref17 ref18 ref19">17&#x2013;19</xref>). Part of the problem is that only a few basic outcome measures related to inflammation (e.g., C-reactive protein, IL-6, IL-8) have been utilized in these studies. This study used a multi-omics approach centered on targeted oxylipins and untargeted proteomics analysis to investigate the influence of 2-weeks dietary nitrate ingestion from a beet-based mixed supplement on exercise-induced inflammation. Oxylipins are upstream regulators of inflammation, increase strongly after prolonged and vigorous exercise, and exert both pro- and anti-inflammatory effects depending on the fatty acid substrate and enzyme system (<xref ref-type="bibr" rid="ref20 ref21 ref22 ref23 ref24">20&#x2013;24</xref>). Untargeted proteomics studies indicate that long endurance cycling and running cause perturbations in numerous immune system and inflammatory proteins (<xref ref-type="bibr" rid="ref25 ref26 ref27">25&#x2013;27</xref>). Previous studies by our research group indicate that exercise-induced changes in inflammatory oxylipins and proteins can be moderated through nutrition-based interventions (<xref ref-type="bibr" rid="ref21 ref22 ref23 ref24">21&#x2013;24</xref>, <xref ref-type="bibr" rid="ref28">28</xref>, <xref ref-type="bibr" rid="ref29">29</xref>). We hypothesized that a multi-omics approach would reveal that 2-weeks ingestion of a beet-based supplement would mitigate exercise-induced inflammation.</p>
</sec>
<sec sec-type="methods" id="sec6">
<title>Methods</title>
<sec id="sec7">
<title>Study participants</title>
<p>Male and female cyclists were invited to take part in this study if they met the inclusion criteria including 18 to 60&#x2009;years of age, capable of cycling 2.25&#x2009;h in a laboratory setting at 70% maximal oxygen consumption rate (VO<sub>2max</sub>), and a willingness to avoid supplements and medications such as non-steroidal anti-inflammatory drugs (NSAIDs) with a potential to influence inflammation. Participants also agreed to limit intake of nitrate-rich vegetables during the study to less than 1 cup per day. These vegetables included spinach, lettuce, beets, beetroot juice, celery, and cabbage. Participants also agreed to avoid the use of mouthwashes, antacids, and chewing gum during the entire 6-week study and the 2-week period prior to the study. During the 3-day period prior to the 2.25&#x2009;h cycling session, subjects agreed to taper exercise training and ingest a moderate-carbohydrate diet using a food list restricting high fat foods and visible fats.</p>
<p>A total of 46 participants were assessed for eligibility and 25 were entered into the study, with 20 completing all aspects of the protocol (<xref ref-type="fig" rid="fig1">Figure 1</xref>). The study participant number provided more than 80% power to detect a difference in pro-inflammatory oxylipins with an effect size 1.06 at alpha 0.05 using two-sample <italic>t</italic>-tests (<xref ref-type="bibr" rid="ref23">23</xref>). Participants voluntarily signed the informed consent, and procedures were approved by the university&#x2019;s Institutional Review Board. Trial Registration: <ext-link xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link>, U.S. National Institutes of Health, identifier: NCT05907135.</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Study participant flow diagram.</p>
</caption>
<graphic xlink:href="fnut-11-1408804-g001.tif"/>
</fig>
</sec>
<sec id="sec8">
<title>Study design</title>
<p>This study employed a randomized, placebo controlled, double-blind, crossover design with two 2-week supplementation periods and a 2-week washout period. The study included seven lab visits at the Appalachian State University Human Performance Laboratory (HPL) at the North Carolina Research Campus, Kannapolis, NC.</p>
<p>During the first two lab visits prior to the 2-week supplementation period, study participants were given a complete orientation to the study protocol, signed the consent form, provided an overnight fasted blood sample, reported demographics and training histories using questionnaires, and recorded responses to the delayed onset of muscle soreness (DOMS) 1&#x2013;10 scale questionnaire (<xref ref-type="bibr" rid="ref30">30</xref>). Height and body weight were assessed, with body composition measured using the BodPod system (Cosmed, Rome, Italy). Study participants were tested for maximal aerobic capacity (VO<sub>2max</sub>) during a graded, cycling test with the Lode cycle ergometer (Lode B.V., Groningen, Netherlands) and the Cosmed CPET metabolic cart (Cosmed, Rome, Italy).</p>
<p>The beet-based (BEET) and placebo (PL) supplements (randomized order using double-blind procedures) for the first and second 2-week supplementation periods were supplied in coded packets. To facilitate compliance to the supplementation protocol, study participants were contacted via email on a regular basis and also returned the coded packets at the end of the supplementation period. Supplements ingested daily (two doses, early morning and mid-day, each mixed in 250&#x2009;mL cold water) for 2-weeks prior to participation in the first 2.25&#x2009;h cycling session. After a 2-week washout period, participants repeated all procedures using the counterbalanced supplement. The BEET and PL supplements were supplied by the sponsor (Standard Process, Palmyra, Wisconsin, USA). Each BEET packet (14 grams) included powder from beets and fermented beets to provide nitrates (106&#x2009;mg of nitrates per serving), green tea extract with caffeine (100&#x2009;mg), Camu Camu to provide vitamin C (22&#x2009;mg), quinoa sprouts to provide B-vitamins (20% of the Daily Value for thiamin, riboflavin, niacin, and vitamin B6), and a mushroom blend of three common mushrooms (1.5&#x2009;g of caterpillar fungus, lion&#x2019;s mane, chaga). The PL supplement included excipients with none of the active ingredients. PL ingredients included a carbohydrate blend (monosaccharides, disaccharides, maltodextrin, corn starch), monk fruit extract, dietary fibers including cellulose and rice bran, rice silica, malic acid, beet flavor, cranberry flavor, and colorants. Participants reported no adverse events from ingesting the supplements over the 2-week periods and were 100% compliant with the supplementation regimen. After the study was completed, study participants responded to a questionnaire regarding &#x201C;what supplement do you think you were taking during each of the 2-week supplementation periods?&#x201D; A total of 22.5 and 60% correctly identified the use of PL and BEET supplements, respectively (Chi-square&#x2009;=&#x2009;12.95, <italic>p</italic> =&#x2009;0.0015). Study participants reported a red color in their urine and stool when using the BEET supplement.</p>
<p>After the 2-week supplementation period, study participants reported to the Human Performance Lab in an overnight fasted state, provided a blood sample, ingested one 14-gram packet of the BEET or PL supplement with 250&#x2009;mL water, and then cycled for 2.25&#x2009;h at high intensity (70% VO<sub>2max</sub>) while ingesting water alone (3&#x2009;mL/kg every 15&#x2009;min). Participants cycled on their own bicycles fitted to Saris H3 direct drive smart trainers (Madison, WI, USA) with monitoring by the Zwift online training platform (Long Beach, CA, USA). Heart rate, cycling speed, cadence, distance, power, breathing rate, ventilation, and oxygen intake were measured after 15&#x2009;min and then every 30&#x2009;min during the cycling session. To ensure performance consistency between trials and to focus on the effect of the BEET supplement on exercise-induced inflammation, performance data from the first trial were used to ensure a similar power and metabolic output during the second trial. Blood samples were collected at 0&#x2009;h, 1.5&#x2009;h, 3&#x2009;h, and 24&#x2009;h post-exercise. After each blood collection, participants provided a DOMS rating. Immediately after the 1.5&#x2009;h post-exercise blood sample, all subjects consumed 7 kilocalories per kilogram of body weight of a fortified nutrient beverage (Boost, Nestl&#x00E9; S.A., Vevey, Switzerland). Blood samples were aliquoted and stored at-80&#x00B0;C prior to analysis for the outcome measures.</p>
</sec>
<sec id="sec9">
<title>Sample analysis</title>
<p>Serum creatine kinase, myoglobin, and coritsol (from serum separator tubes), and complete blood counts (CBCs) with a white blood cell differential count (EDTA tubes) were analyzed using Labcorp services (Burlington, NC). Plasma aliquots were prepared from EDTA blood collection tubes and stored in a-80&#x00B0;C freezer until analysis for nitrate, nitrite, proteomics, and oxylipins after the study was completed.</p>
<sec id="sec10">
<title>Plasma nitrate and nitrite</title>
<p>The nitrate/nitrite fluorometric assay kit (item # 780051) from the Cayman Chemical Company (Ann Arbor, MI) was used to measure plasma concentrations of nitrate (NO<sub>3</sub><sup>&#x2212;</sup>) and nitrite (NO<sub>2</sub><sup>&#x2212;</sup>). This assay was performed in accordance with the instructions provided by the manufacturer with the plates read using the SpectraMax iD3 Multi-Mode Microplate Reader (Molecular Devices, LLC San Jose, CA, USA). Data were processed using BioTek Gen5 2.0 software (BioTek, Agilent, Santa Clara, CA, USA). Samples were analyzed in duplicate (mean coefficient of variation or CV of 9.8%). The sum of both NO<sub>3</sub><sup>&#x2212;</sup> and nitrite NO<sub>2</sub><sup>&#x2212;</sup> was used as an index of total nitric oxide production as recommended by Cayman (lower limit of detection 0.70&#x2009;&#x03BC;M, intra-assay CV 2.7%). The process includes 2 steps: conversion of nitrate to nitrite using a nitrate reductase, followed by addition of an acidic solution (DAN) which isolates nitrate and yields the product 1(H)-naphthotriazole. Sodium hydroxide (NaOH) is then added to enhance fluorescence of the product. Sample concentrations were plotted along a standard curve, which was made using fresh standards provided in the assay kits.</p>
</sec>
<sec id="sec11">
<title>Plasma oxylipins</title>
<p>Plasma arachidonic acid (ARA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and oxylipins were analyzed using a liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) method as fully described elsewhere (<xref ref-type="bibr" rid="ref31">31</xref>). Resultant data files were processed with Skyline, and the auto-integrated peaks were inspected manually. Concentrations of each oxylipin were determined from calibration curves of each analyte, which were constructed by normalizing to the selected deuterated internal standards followed by linear regression with 1/x weighting (<xref ref-type="supplementary-material" rid="SM1">Supplement Data Sheet 1</xref>). The coefficient of variation for the quality control standards was &#x003C;15% as reported in the method development paper (<xref ref-type="bibr" rid="ref31">31</xref>). A total of 41 of 67 oxylipins detected increased significantly post-exercise, and these were grouped for statistical analysis. Seven oxylipins generated from arachidonic acid and cytochrome P-450 (ARA-CYP) were grouped and these included 5,6-, 8,9-, 11,12-, and 14,15-dihydroxy-eicosatetraenoic acid (diHETrEs), 16-, 17-hydroxy-eicosatetraenoic acids (HETEs), and the 20-HETE metabolite 20-carboxy-arachidonic acid (20-coohAA). Four abundant oxylipins generated from linoleic acid (LA) with CYP and lipoxygenease (LOX) were also grouped, including 9,10- dihydroxy-9Z-octadecenoic acid (DiHOME), 12,13-DiHOME, 9- hydroxy-octadecadienoic acid (HODE), and 13-HODE (LA-DiHOMES + HODES).</p>
</sec>
<sec id="sec12">
<title>Plasma proteome and statistical procedures</title>
<p>Untargeted proteomics were conducted using methods previously described (<xref ref-type="bibr" rid="ref22">22</xref>, <xref ref-type="bibr" rid="ref32">32</xref>). Briefly, after sample preparation, 200&#x2009;ng peptides from the plasma samples were loaded onto disposable EvoTip trap-columns (EV-2003, EvoSep, Denmark) and separated on an EvoSep One &#x2122; LC system (EV-1000, EvoSep, Denmark) using a 21&#x2009;min gradient with 1&#x2009;&#x03BC;L/min flow rate. Effluents were analyzed on a high resolution Orbitrap Exploris 240 (Thermo) mass spectrometer using the data independent acquisition (DIA) method. The plasma protein library was generated using the gas-phase fractionation DIA method from peptide samples with and without depletion of the top 14 high-abundance plasma proteins (14,120 precursors, 960 proteins). The obtained LC&#x2013;MS/MS dataset was searched for protein identification and quantitation using DIA-NN (<xref ref-type="bibr" rid="ref33">33</xref>). Data were normalized by referencing to the protein levels of the first time point from the same individual subject to effectively correct for inter-individual variations (<xref ref-type="bibr" rid="ref34">34</xref>) (<xref ref-type="supplementary-material" rid="SM2">Supplementary Data Sheet 2</xref>). The normalized values were statistically analyzed using the ANOVA test with two trials and six timepoints. To consider the protein as significantly changing between or within effects, the <italic>p</italic>-value was set to less than 0.05. Maximum likelihood-based hierarchical clustering analysis was used to cluster proteins with similar level patterns, and the results were visualized as a heatmap with the averaged value of each time-point after normalization by z-score. The list of significantly changed proteins in the enriched clusters were functionally enriched using STRING (Ver.11.5).<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref> The top enriched biological processes from STRING analysis were selected to represent the functions of the proteins.</p>
</sec>
</sec>
<sec id="sec13">
<title>Additional statistical procedures</title>
<p>The data are expressed as mean&#x2009;&#x00B1;&#x2009;SE and were analyzed using the generalized linear model (GLM), repeated measures ANOVA module in SPSS (IBM SPSS Statistics, Version 28.0, IBM Corp, Armonk, NY, USA). The statistical model utilized the within-subjects approach: 2 (trials) x 6 (time points) repeated measures ANOVA and provided time (i.e., the collective effect of the cycling exercise bout) and interaction effects (i.e., whether the data pattern over time differed between trials). If the interaction effect was significant (<italic>p</italic> &#x2264;&#x2009;0.05), then post-hoc analyses were conducted using paired <italic>t</italic>-tests comparing time point contrasts between trials. An alpha level of <italic>p</italic> &#x2264;&#x2009;0.01 was used after Bonferroni correction for 5 multiple tests. The positive false discovery rate (FDR or &#x201C;q-value&#x201D;) was calculated for multiple testing correction of the plasma oxylipin and plasma proteomics data. Cohen&#x2019;s d effect size was calculated for the oxylipin data as the mean difference between the trials at the immediate post-exercise time point divided by the pooled standard deviation.</p>
</sec>
</sec>
<sec sec-type="results" id="sec14">
<title>Results</title>
<p><xref ref-type="table" rid="tab1">Table 1</xref> summarizes characteristics for the <italic>n</italic>&#x2009;=&#x2009;20 study participants (<italic>n</italic>&#x2009;=&#x2009;14 males, <italic>n</italic>&#x2009;=&#x2009;6 females) who completed the study protocol. Age, percent body fat, aerobic capacity (VO2max), and training volume were similar between the male and female cyclists. The pattern of change over time did not differ between the male and female cyclists for a key outcome measurement (total plasma oxylipins, supplement x time x sex interaction effect, <italic>p</italic>-value =0.835). Thus, outcome measures for this randomized, crossover study are presented for all participants combined.</p>
<table-wrap position="float" id="tab1">
<label>Table 1</label>
<caption>
<p>Subject characteristics (<italic>n</italic>&#x2009;=&#x2009;20) for male (<italic>n</italic>&#x2009;=&#x2009;14) and female (<italic>n</italic>&#x2009;=&#x2009;6) cyclists.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th/>
<th align="center" valign="top">Sex</th>
<th align="center" valign="top">Mean</th>
<th align="center" valign="top">SE</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="2">Age (years)</td>
<td align="center" valign="top">M&#x2009;=&#x2009;male</td>
<td align="center" valign="middle">46.5</td>
<td align="center" valign="middle">2.6</td>
</tr>
<tr>
<td align="center" valign="top">F&#x2009;=&#x2009;female</td>
<td align="center" valign="middle">51.3</td>
<td align="center" valign="middle">4.3</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Body mass (kg)</td>
<td align="center" valign="top">M</td>
<td align="center" valign="middle">80.5&#x002A;</td>
<td align="center" valign="middle">3.5</td>
</tr>
<tr>
<td align="center" valign="top">F</td>
<td align="center" valign="middle">60.2</td>
<td align="center" valign="middle">2.6</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Height (cm)</td>
<td align="center" valign="top">M</td>
<td align="center" valign="middle">179&#x002A;</td>
<td align="center" valign="middle">1.6</td>
</tr>
<tr>
<td align="center" valign="top">F</td>
<td align="center" valign="middle">167</td>
<td align="center" valign="middle">1.6</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Body mass index (BMI) (kg/m<sup>2</sup>)</td>
<td align="center" valign="top">M</td>
<td align="center" valign="middle">25.0&#x002A;</td>
<td align="center" valign="middle">0.9</td>
</tr>
<tr>
<td align="center" valign="top">F</td>
<td align="center" valign="middle">21.7</td>
<td align="center" valign="middle">1.0</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Body fat (%)</td>
<td align="center" valign="top">M</td>
<td align="center" valign="middle">19.5</td>
<td align="center" valign="middle">1.8</td>
</tr>
<tr>
<td align="center" valign="top">F</td>
<td align="center" valign="middle">25.0</td>
<td align="center" valign="middle">3.7</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Maximum oxygen consumption (VO<sub>2max</sub>) (mL<sup>.</sup>kg.<sup>&#x2212;1</sup>&#x2009;min<sup>&#x2212;1</sup>)</td>
<td align="center" valign="top">M</td>
<td align="center" valign="middle">41.2</td>
<td align="center" valign="middle">1.6</td>
</tr>
<tr>
<td align="center" valign="top">F</td>
<td align="center" valign="middle">40.9</td>
<td align="center" valign="middle">2.9</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Maximum heart rate (beats/min)</td>
<td align="center" valign="top">M</td>
<td align="center" valign="middle">170</td>
<td align="center" valign="middle">4.0</td>
</tr>
<tr>
<td align="center" valign="top">F</td>
<td align="center" valign="middle">160</td>
<td align="center" valign="middle">3.8</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Maximum watts</td>
<td align="center" valign="top">M</td>
<td align="center" valign="middle">282&#x002A;</td>
<td align="center" valign="middle">12.4</td>
</tr>
<tr>
<td align="center" valign="top">F</td>
<td align="center" valign="middle">217</td>
<td align="center" valign="middle">20.1</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Cycling training distance (km/wk)</td>
<td align="center" valign="top">M</td>
<td align="center" valign="middle">124</td>
<td align="center" valign="middle">18.2</td>
</tr>
<tr>
<td align="center" valign="top">F</td>
<td align="center" valign="middle">139</td>
<td align="center" valign="middle">31.1</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>&#x002A;<italic>p</italic>&#x2009;&#x2264;&#x2009;0.05.</p>
</table-wrap-foot>
</table-wrap>
<p>Performance data for each trial are summarized in <xref ref-type="table" rid="tab2">Table 2</xref>. As designed, the two trials were similar in all cycling performance measures including total distance cycled, and percent of maximal heart rates, watts, and oxygen consumption rates.</p>
<table-wrap position="float" id="tab2">
<label>Table 2</label>
<caption>
<p>Average 2.25&#x2009;h cycling performance outcomes for <italic>n</italic>&#x2009;=&#x2009;20 cyclists (mean&#x2009;&#x00B1;&#x2009;SE).</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top" colspan="2">Performance measurement</th>
<th align="center" valign="top">Mean&#x2009;&#x00B1;&#x2009;SE</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="2">Cycling power (watts)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">161&#x2009;&#x00B1;&#x2009;6.9 (61.9&#x2009;&#x00B1;&#x2009;1.4% max)</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">164&#x2009;&#x00B1;&#x2009;6.8 (63.0&#x2009;&#x00B1;&#x2009;1.3% max)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Heart rate (beats/min)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">131&#x2009;&#x00B1;&#x2009;2.6 (78.9&#x2009;&#x00B1;&#x2009;1.7% max)</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">132&#x2009;&#x00B1;&#x2009;2.8 (80.2&#x2009;&#x00B1;&#x2009;1.8% max)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Oxygen consumption rate (VO<sub>2</sub>) (ml<sup>.</sup>kg<sup>.-1</sup>&#x2009;min<sup>&#x2212;1</sup>)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">30.1&#x2009;&#x00B1;&#x2009;1.1 (73.6&#x2009;&#x00B1;&#x2009;2.1% max)</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">31.7&#x2009;&#x00B1;&#x2009;1.1 (77.5&#x2009;&#x00B1;&#x2009;2.2% max)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Respiratory exchange ratio (RER)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">0.834&#x2009;&#x00B1;&#x2009;0.001</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">0.817&#x2009;&#x00B1;&#x2009;0.007</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Distance cycled (km)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">64.9&#x2009;&#x00B1;&#x2009;1.6</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">65.7&#x2009;&#x00B1;&#x2009;1.7</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Elevation gain (m)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">314&#x2009;&#x00B1;&#x2009;33.0</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">282&#x2009;&#x00B1;&#x2009;24.2</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Speed (km/h)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">27.7&#x2009;&#x00B1;&#x2009;1.1</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">29.1&#x2009;&#x00B1;&#x2009;0.6</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Cycling cadence (pedal revolutions/min)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">71.4&#x2009;&#x00B1;&#x2009;2.9</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">74.0&#x2009;&#x00B1;&#x2009;1.8</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Weight change (kg)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">1.13&#x2009;&#x00B1;&#x2009;0.11</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">1.08&#x2009;&#x00B1;&#x2009;0.13</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p>No significant placebo (PL) vs. BEET trial differences in performance measurements were found as designed.</p>
</table-wrap-foot>
</table-wrap>
<p>Data for delayed onset of muscle soreness (DOMS), muscle damage biomarkers, the neutrophil/lymphocyte ratio, and serum cortisol are summarized in <xref ref-type="table" rid="tab3">Table 3</xref>. Time effects for each of these variables were significant but the patterns of increase did not differ significantly between the BEET and PL trials (interaction effects, <italic>p</italic>-values &#x003E;0.05).</p>
<table-wrap position="float" id="tab3">
<label>Table 3</label>
<caption>
<p>Trial comparisons for <italic>n</italic>&#x2009;=&#x2009;20 participants across all time points for muscle soreness&#x002A; and damage markers (serum creatine kinase and myoglobin), the neutrophil/lymphocyte blood count ratio, and serum cortisol.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Variable</th>
<th align="center" valign="top">Trial</th>
<th align="center" valign="top">Pre- Study</th>
<th align="center" valign="top">2-Wks Suppl.</th>
<th align="center" valign="top">0&#x2009;h Post-Ex</th>
<th align="center" valign="top">1.5&#x2009;h Post-Ex</th>
<th align="center" valign="top">3&#x2009;h Post-Ex</th>
<th align="center" valign="top">24&#x2009;h Post-Ex</th>
<th align="center" valign="top"><italic>p</italic>- value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="2">DOMS (1&#x2013;10 scale)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">1.7&#x2009;&#x00B1;&#x2009;0.3</td>
<td align="center" valign="top">1.7&#x2009;&#x00B1;&#x2009;0.2</td>
<td align="center" valign="top">4.1&#x2009;&#x00B1;&#x2009;0.4</td>
<td align="center" valign="top">3.6&#x2009;&#x00B1;&#x2009;0.4</td>
<td align="center" valign="top">2.7&#x2009;&#x00B1;&#x2009;0.3</td>
<td align="center" valign="top">1.9&#x2009;&#x00B1;&#x2009;0.2</td>
<td align="center" valign="top" rowspan="2">&#x003C;0.001; 0.069</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">2.1&#x2009;&#x00B1;&#x2009;0.4</td>
<td align="center" valign="top">1.6&#x2009;&#x00B1;&#x2009;0.2</td>
<td align="center" valign="top">4.2&#x2009;&#x00B1;&#x2009;0.4</td>
<td align="center" valign="top">3.3&#x2009;&#x00B1;&#x2009;0.4</td>
<td align="center" valign="top">2.5&#x2009;&#x00B1;&#x2009;0.3</td>
<td align="center" valign="top">2.1&#x2009;&#x00B1;&#x2009;0.2</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Creatine kinase (U/L)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">143&#x2009;&#x00B1;&#x2009;14.4</td>
<td align="center" valign="top">141&#x2009;&#x00B1;&#x2009;17.1</td>
<td align="center" valign="top">177&#x2009;&#x00B1;&#x2009;24.3</td>
<td align="center" valign="top">166&#x2009;&#x00B1;&#x2009;21.4</td>
<td align="center" valign="top">172&#x2009;&#x00B1;&#x2009;22.9</td>
<td align="center" valign="top">158&#x2009;&#x00B1;&#x2009;22.3</td>
<td align="center" valign="top" rowspan="2">0.008; 0.974</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">174&#x2009;&#x00B1;&#x2009;21.4</td>
<td align="center" valign="top">174&#x2009;&#x00B1;&#x2009;23.7</td>
<td align="center" valign="top">279&#x2009;&#x00B1;&#x2009;83.1</td>
<td align="center" valign="top">266&#x2009;&#x00B1;&#x2009;81.9</td>
<td align="center" valign="top">266&#x2009;&#x00B1;&#x2009;77.8</td>
<td align="center" valign="top">229&#x2009;&#x00B1;&#x2009;50.5</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Myoglobin (ng/ml)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">35.5&#x2009;&#x00B1;&#x2009;2.9</td>
<td align="center" valign="top">32.4&#x2009;&#x00B1;&#x2009;1.9</td>
<td align="center" valign="top">47.4&#x2009;&#x00B1;&#x2009;3.9</td>
<td align="center" valign="top">58.1&#x2009;&#x00B1;&#x2009;10.0</td>
<td align="center" valign="top">52.0&#x2009;&#x00B1;&#x2009;9.2</td>
<td align="center" valign="top">36.7&#x2009;&#x00B1;&#x2009;3.1</td>
<td align="center" valign="top" rowspan="2">0.002; 0.595</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">40.1&#x2009;&#x00B1;&#x2009;3.5</td>
<td align="center" valign="top">34.1&#x2009;&#x00B1;&#x2009;2.1</td>
<td align="center" valign="top">57.0&#x2009;&#x00B1;&#x2009;6.6</td>
<td align="center" valign="top">67.0&#x2009;&#x00B1;&#x2009;6.8</td>
<td align="center" valign="top">63.7&#x2009;&#x00B1;&#x2009;9.3</td>
<td align="center" valign="top">38.0&#x2009;&#x00B1;&#x2009;3.6</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Neutrophil/lymphocyte</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">1.6&#x2009;&#x00B1;&#x2009;0.1</td>
<td align="center" valign="top">1.5&#x2009;&#x00B1;&#x2009;0.1</td>
<td align="center" valign="top">4.0&#x2009;&#x00B1;&#x2009;0.4</td>
<td align="center" valign="top">5.2&#x2009;&#x00B1;&#x2009;0.5</td>
<td align="center" valign="top">4.9&#x2009;&#x00B1;&#x2009;0.5</td>
<td align="center" valign="top">1.7&#x2009;&#x00B1;&#x2009;0.2</td>
<td align="center" valign="top" rowspan="2">&#x003C;0.001; 0.163</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">1.6&#x2009;&#x00B1;&#x2009;0.2</td>
<td align="center" valign="top">1.6&#x2009;&#x00B1;&#x2009;0.2</td>
<td align="center" valign="top">4.2&#x2009;&#x00B1;&#x2009;0.5</td>
<td align="center" valign="top">6.1&#x2009;&#x00B1;&#x2009;0.7</td>
<td align="center" valign="top">5.5&#x2009;&#x00B1;&#x2009;0.6</td>
<td align="center" valign="top">1.8&#x2009;&#x00B1;&#x2009;0.2</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">Cortisol (&#x03BC;g/dl)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">14.0&#x2009;&#x00B1;&#x2009;0.8</td>
<td align="center" valign="top">15.4&#x2009;&#x00B1;&#x2009;0.8</td>
<td align="center" valign="top">16.9&#x2009;&#x00B1;&#x2009;1.2</td>
<td align="center" valign="top">11.8&#x2009;&#x00B1;&#x2009;1.0</td>
<td align="center" valign="top">9.7&#x2009;&#x00B1;&#x2009;0.6</td>
<td align="center" valign="top">14.3&#x2009;&#x00B1;&#x2009;0.9</td>
<td align="center" valign="top" rowspan="2">&#x003C;0.001; 0.682</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">13.8&#x2009;&#x00B1;&#x2009;0.8</td>
<td align="center" valign="top">14.8&#x2009;&#x00B1;&#x2009;0.8</td>
<td align="center" valign="top">18.3&#x2009;&#x00B1;&#x2009;1.4</td>
<td align="center" valign="top">13.3&#x2009;&#x00B1;&#x2009;1.1</td>
<td align="center" valign="top">11.0&#x2009;&#x00B1;&#x2009;0.8</td>
<td align="center" valign="top">14.7&#x2009;&#x00B1;&#x2009;0.7</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>P</italic>-values represent time (first value) and trial x time interaction effects. <sup>&#x002A;</sup>Ex, exercise; Suppl, supplement; PL, placebo; DOMS, delayed onset of muscle soreness.</p>
</table-wrap-foot>
</table-wrap>
<p>BEET compared to placebo intake was associated with a significant increase in the sum of plasma nitrate and nitrite (NA&#x2009;+&#x2009;NI) (time and interaction effects, both <italic>p</italic>&#x2009;&#x003C;&#x2009;0.001) (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The increase in NA&#x2009;+&#x2009;NI was significantly different between the BEET and PL trials after 2-weeks supplementation and throughout at least 3&#x2009;h of recovery from the cycling bout. Trial differences for NA&#x2009;+&#x2009;NI at 24&#x2009;h post-exercise tended to be different (<italic>p</italic>&#x2009;=&#x2009;0.089).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>Change in the sum of plasma nitrate and nitrite after 2-weeks BEET and placebo supplementation and during 24&#x2009;h recovery from 2.25&#x2009;h cycling in <italic>n</italic>&#x2009;=&#x2009;20 cyclists. Time and interaction effects, both <italic>p</italic>&#x2009;&#x003C;&#x2009;0.001.</p>
</caption>
<graphic xlink:href="fnut-11-1408804-g002.tif"/>
</fig>
<p>Plasma arachidonic acid (ARA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA) increased significantly post-exercise (time effects, <italic>p</italic>&#x2009;&#x003C;&#x2009;0.001) with no significant interaction effects (all <italic>p</italic>&#x2009;&#x003E;&#x2009;0.50) (<xref ref-type="supplementary-material" rid="SM1">Supplementary Data Sheet 1</xref>). A total of 67 oxylipins were detected in study samples. Of these, 41 oxylipins increased significantly post-exercise (<xref ref-type="supplementary-material" rid="SM1">Supplementary Data Sheet 1</xref>). These 41 oxylipins were summed for a composite variable and analysis showed significant post-exercise increases without trial differences between BEET and PL (interaction effect, <italic>p</italic>&#x2009;=&#x2009;0.166) (Cohen&#x2019;s <italic>d</italic> =&#x2009;0.219, immediately post-exercise) (<xref ref-type="table" rid="tab4">Table 4</xref>). Three other composite variables were calculated including seven oxylipins generated from arachidonic acid and cytochrome P-450 (ARA-CYP), two abundant oxylipins generated from linoleic acid and CYP (9,10-DiHOME, 12,13-DiHOME), and two abundant oxylipins generated from lipoxygenase (LOX) (9-HODE, 13-HODE) (<xref ref-type="table" rid="tab4">Table 4</xref>). Significant time effects were shown for each of these composite oxylipin variables but without significant interaction effects (<xref ref-type="table" rid="tab4">Table 4</xref>) (Cohen&#x2019;s <italic>d</italic> =&#x2009;0.102, 0.221, 0.283, respectively, immediately post-exercise). Two anti-inflammatory oxylipins were significantly higher in the BEET versus PL trials (<xref ref-type="fig" rid="fig3">Figures 3A</xref>,<xref ref-type="fig" rid="fig3">B</xref>). These included the EPA-derived oxylipin 18-hydroxyeicosapentaenoic acid (18-HEPE) (time effect, <italic>p</italic>&#x2009;&#x003C;&#x2009;0.001, interaction effect, <italic>p</italic>&#x2009;=&#x2009;0.016) and the DHA-derived oxylipin 4-hydroxydocosahexaenoic acid (4-HDoHE) (time effect <italic>p</italic>&#x2009;&#x003C;&#x2009;0.001, interaction effect, <italic>p</italic>&#x2009;=&#x2009;0.010).</p>
<table-wrap position="float" id="tab4">
<label>Table 4</label>
<caption>
<p>Trial comparisons across all time points for total plasma oxylipins and oxylipin subgroups.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Variable (ng/mL)</th>
<th align="center" valign="top">Trial</th>
<th align="center" valign="top">Pre- Suppl.</th>
<th align="center" valign="top">2-Wks Suppl.</th>
<th align="center" valign="top">0&#x2009;h Post-Ex</th>
<th align="center" valign="top">1.5&#x2009;h Post-Ex</th>
<th align="center" valign="top">3&#x2009;h Post-Ex</th>
<th align="center" valign="top">24&#x2009;h Post-Ex</th>
<th align="center" valign="top"><italic>p</italic>- value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="2">Oxylipins, total (<italic>n</italic>&#x2009;=&#x2009;41 oxylipins)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">21.3&#x2009;&#x00B1;&#x2009;1.7</td>
<td align="center" valign="top">24.1&#x2009;&#x00B1;&#x2009;2.9</td>
<td align="center" valign="top">67.3&#x2009;&#x00B1;&#x2009;6.2</td>
<td align="center" valign="top">35.0&#x2009;&#x00B1;&#x2009;3.3</td>
<td align="center" valign="top">32.5&#x2009;&#x00B1;&#x2009;8.3</td>
<td align="center" valign="top">19.3&#x2009;&#x00B1;&#x2009;1.2</td>
<td align="center" valign="top" rowspan="2">&#x003C;0.001; 0.166</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">21.2&#x2009;&#x00B1;&#x2009;1.7</td>
<td align="center" valign="top">20.5&#x2009;&#x00B1;&#x2009;1.4</td>
<td align="center" valign="top">76.4&#x2009;&#x00B1;&#x2009;11.6</td>
<td align="center" valign="top">37.7&#x2009;&#x00B1;&#x2009;4.4</td>
<td align="center" valign="top">31.9&#x2009;&#x00B1;&#x2009;8.7</td>
<td align="center" valign="top">20.3&#x2009;&#x00B1;&#x2009;1.3</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">DiHOMES (9,10&#x2009;+&#x2009;12,13)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">3.2&#x2009;&#x00B1;&#x2009;0.5</td>
<td align="center" valign="top">3.8&#x2009;&#x00B1;&#x2009;0.7</td>
<td align="center" valign="top">10.4&#x2009;&#x00B1;&#x2009;1.0</td>
<td align="center" valign="top">3.9&#x2009;&#x00B1;&#x2009;0.6</td>
<td align="center" valign="top">5.9&#x2009;&#x00B1;&#x2009;2.7</td>
<td align="center" valign="top">2.5&#x2009;&#x00B1;&#x2009;0.2</td>
<td align="center" valign="top" rowspan="2">&#x003C;0.001; 0.255</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">3.1&#x2009;&#x00B1;&#x2009;0.5</td>
<td align="center" valign="top">2.6&#x2009;&#x00B1;&#x2009;0.3</td>
<td align="center" valign="top">11.6&#x2009;&#x00B1;&#x2009;1.4</td>
<td align="center" valign="top">3.6&#x2009;&#x00B1;&#x2009;0.6</td>
<td align="center" valign="top">6.6&#x2009;&#x00B1;&#x2009;3.4</td>
<td align="center" valign="top">2.7&#x2009;&#x00B1;&#x2009;0.3</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">HODES (9&#x2009;+&#x2009;13)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="bottom">5.7&#x2009;&#x00B1;&#x2009;0.9</td>
<td align="center" valign="bottom">7.6&#x2009;&#x00B1;&#x2009;1.5</td>
<td align="center" valign="bottom">25.7&#x2009;&#x00B1;&#x2009;2.6</td>
<td align="center" valign="bottom">8.9&#x2009;&#x00B1;&#x2009;1.2</td>
<td align="center" valign="bottom">9.3&#x2009;&#x00B1;&#x2009;4.9</td>
<td align="center" valign="bottom">4.7&#x2009;&#x00B1;&#x2009;0.4</td>
<td align="center" valign="top" rowspan="2">0.002; 0.094</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="bottom">6.0&#x2009;&#x00B1;&#x2009;1.0</td>
<td align="center" valign="bottom">5.2&#x2009;&#x00B1;&#x2009;0.4</td>
<td align="center" valign="bottom">31.8&#x2009;&#x00B1;&#x2009;6.3</td>
<td align="center" valign="bottom">9.1&#x2009;&#x00B1;&#x2009;1.9</td>
<td align="center" valign="bottom">7.9&#x2009;&#x00B1;&#x2009;4.4</td>
<td align="center" valign="bottom">5.0&#x2009;&#x00B1;&#x2009;0.5</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="2">ARA-CYP&#x002A; (<italic>n</italic>&#x2009;=&#x2009;7 oxylipins)</td>
<td align="center" valign="top">PL</td>
<td align="center" valign="top">4.5&#x2009;&#x00B1;&#x2009;0.3</td>
<td align="center" valign="top">4.6&#x2009;&#x00B1;&#x2009;0.3</td>
<td align="center" valign="top">8.4&#x2009;&#x00B1;&#x2009;0.8</td>
<td align="center" valign="top">10.6&#x2009;&#x00B1;&#x2009;1.0</td>
<td align="center" valign="top">8.8&#x2009;&#x00B1;&#x2009;0.9</td>
<td align="center" valign="top">4.9&#x2009;&#x00B1;&#x2009;0.3</td>
<td align="center" valign="top" rowspan="2">&#x003C;0.001; 0.163</td>
</tr>
<tr>
<td align="center" valign="top">BEET</td>
<td align="center" valign="top">4.5&#x2009;&#x00B1;&#x2009;0.4</td>
<td align="center" valign="top">4.7&#x2009;&#x00B1;&#x2009;0.4</td>
<td align="center" valign="top">9.3&#x2009;&#x00B1;&#x2009;1.0</td>
<td align="center" valign="top">13.6&#x2009;&#x00B1;&#x2009;1.9</td>
<td align="center" valign="top">10.3&#x2009;&#x00B1;&#x2009;1.4</td>
<td align="center" valign="top">4.9&#x2009;&#x00B1;&#x2009;0.4</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<p><italic>p</italic>-values represent time (first value) and trial x time interaction effects. <sup>&#x002A;</sup>ARA-CYP&#x2009;=&#x2009;7 oxylipins generated from arachidonic acid and cytochrome P-450 (ARA-CYP) were grouped and these included 5,6-, 8,9-, 11,12-, and 14,15-dihydroxy-eicosatetraenoic acid (diHETrEs), 16-, 17-hydroxy-eicosatetraenoic acids (HETEs), and the 20-HETE metabolite 20-carboxy-arachidonic acid (20-coohAA).</p>
</table-wrap-foot>
</table-wrap>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>Change in <bold>(A)</bold> plasma HEPE-18 and <bold>(B)</bold> 4-HDoHE in BEET and placebo trials during 24&#x2009;h recovery from 2.25&#x2009;h cycling in <italic>n</italic>&#x2009;=&#x2009;20 cyclists. Interaction effect, <italic>p</italic>&#x2009;=&#x2009;0.016 and 0.010, respectively.</p>
</caption>
<graphic xlink:href="fnut-11-1408804-g003.tif"/>
</fig>
<p>A total of 616 plasma proteins were identified with no missing data for 458 proteins across all time points (<xref ref-type="supplementary-material" rid="SM2">Supplementary Data Sheet 2</xref>). Two-way ANOVA analysis of the normalized data showed that 45 proteins were lower and 21 proteins were higher in the BEET versus PL trials (all <italic>p</italic>&#x2009;&#x003C;&#x2009;0.05). The heatmap and line graphs of the clustered proteins are shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>, and the identity of the clustered proteins is summarized in <xref ref-type="table" rid="tab5">Table 5</xref>. Functional enrichment and protein&#x2013;protein interaction networks are depicted in <xref ref-type="fig" rid="fig5">Figure 5</xref> and supported a linkage of BEET supplementation with reduced complement activation and inflammatory responses, metabolic process and negative regulation of biological processes, and responses to stimulus, and an increased regulation of insulin-like growth factors (IGF) and uptake of IGF binding proteins, and symbiotic interactions.</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>Heatmap and line graphs of clustered proteins in the BEET and placebo trials. T1, pre-study; T2, 2-weeks supplementation, pre-exercise; T3, immediately post-exercise (2.25&#x2009;h cycling bout); T4, 1.5&#x2009;h post-exercise; T5, 3&#x2009;h post-exercise; T6, 24&#x2009;h post-exercise.</p>
</caption>
<graphic xlink:href="fnut-11-1408804-g004.tif"/>
</fig>
<table-wrap position="float" id="tab5">
<label>Table 5</label>
<caption>
<p>List of 45 proteins that were lower and 21 proteins that were higher with BEET compared to placebo supplementation.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="top">Protein ID</th>
<th align="left" valign="top">Gene</th>
<th align="left" valign="top">Protein description</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top" colspan="3">Lower in BEET trial</td>
</tr>
<tr>
<td align="left" valign="top">Q9BXT5; Q9Y4L1</td>
<td align="left" valign="top">HYOU1</td>
<td align="left" valign="top">Hypoxia up-regulated protein 1</td>
</tr>
<tr>
<td align="left" valign="top">Q9ULV4</td>
<td align="left" valign="top">CORO1C</td>
<td align="left" valign="top">Coronin-1C</td>
</tr>
<tr>
<td align="left" valign="top">Q96KN2</td>
<td align="left" valign="top">CNDP1</td>
<td align="left" valign="top">Beta-Ala-His dipeptidase</td>
</tr>
<tr>
<td align="left" valign="top">Q86UX7</td>
<td align="left" valign="top">FERMT3</td>
<td align="left" valign="top">Fermitin family homolog 3</td>
</tr>
<tr>
<td align="left" valign="top">Q6UXB8</td>
<td align="left" valign="top">PI16</td>
<td align="left" valign="top">Peptidase inhibitor 16</td>
</tr>
<tr>
<td align="left" valign="top">Q06830</td>
<td align="left" valign="top">PRDX1</td>
<td align="left" valign="top">Peroxiredoxin-1</td>
</tr>
<tr>
<td align="left" valign="top">Q03181</td>
<td align="left" valign="top">PPARD</td>
<td align="left" valign="top">Peroxisome proliferator-activated receptor delta</td>
</tr>
<tr>
<td align="left" valign="top">P80748</td>
<td align="left" valign="top">IGLV3-21</td>
<td align="left" valign="top">Immunoglobulin lambda variable 3&#x2013;21</td>
</tr>
<tr>
<td align="left" valign="top">P78509</td>
<td align="left" valign="top">RELN</td>
<td align="left" valign="top">Reelin</td>
</tr>
<tr>
<td align="left" valign="top">P52566</td>
<td align="left" valign="top">ARHGDIB</td>
<td align="left" valign="top">Rho GDP-dissociation inhibitor 2</td>
</tr>
<tr>
<td align="left" valign="top">P40197</td>
<td align="left" valign="top">GP5</td>
<td align="left" valign="top">Platelet glycoprotein V</td>
</tr>
<tr>
<td align="left" valign="top">P35916</td>
<td align="left" valign="top">FLT4</td>
<td align="left" valign="top">Vascular endothelial growth factor receptor 3</td>
</tr>
<tr>
<td align="left" valign="top">P30086</td>
<td align="left" valign="top">PEBP1</td>
<td align="left" valign="top">Phosphatidylethanolamine-binding protein 1</td>
</tr>
<tr>
<td align="left" valign="top">P27918</td>
<td align="left" valign="top">CFP</td>
<td align="left" valign="top">Properdin</td>
</tr>
<tr>
<td align="left" valign="top">P27487</td>
<td align="left" valign="top">DPP4</td>
<td align="left" valign="top">Dipeptidyl peptidase 4</td>
</tr>
<tr>
<td align="left" valign="top">P23142</td>
<td align="left" valign="top">FBLN1</td>
<td align="left" valign="top">Fibulin-1</td>
</tr>
<tr>
<td align="left" valign="top">P19021</td>
<td align="left" valign="top">PAM</td>
<td align="left" valign="top">Peptidyl-glycine alpha-amidating monooxygenase</td>
</tr>
<tr>
<td align="left" valign="top">P15531; P22392; O60361</td>
<td align="left" valign="top">NME1;NME2</td>
<td align="left" valign="top">Nucleoside diphosphate kinase A</td>
</tr>
<tr>
<td align="left" valign="top">P13727</td>
<td align="left" valign="top">PRG2</td>
<td align="left" valign="top">Bone marrow proteoglycan</td>
</tr>
<tr>
<td align="left" valign="top">P13647</td>
<td align="left" valign="top">KRT5</td>
<td align="left" valign="top">Keratin, type II cytoskeletal 5</td>
</tr>
<tr>
<td align="left" valign="top">P11597</td>
<td align="left" valign="top">CETP</td>
<td align="left" valign="top">Cholesteryl ester transfer protein</td>
</tr>
<tr>
<td align="left" valign="top">P10909</td>
<td align="left" valign="top">CLU</td>
<td align="left" valign="top">Clusterin</td>
</tr>
<tr>
<td align="left" valign="top">P10586</td>
<td align="left" valign="top">PTPRF</td>
<td align="left" valign="top">Receptor-type tyrosine-protein phosphatase F</td>
</tr>
<tr>
<td align="left" valign="top">P0DJI8; P0DJI9</td>
<td align="left" valign="top">SAA1</td>
<td align="left" valign="top">Serum amyloid A-1 protein</td>
</tr>
<tr>
<td align="left" valign="top">P08581</td>
<td align="left" valign="top">MET</td>
<td align="left" valign="top">Hepatocyte growth factor receptor</td>
</tr>
<tr>
<td align="left" valign="top">P06312</td>
<td align="left" valign="top">IGKV4-1</td>
<td align="left" valign="top">Immunoglobulin kappa variable 4&#x2013;1</td>
</tr>
<tr>
<td align="left" valign="top">P05062</td>
<td align="left" valign="top">ALDOB</td>
<td align="left" valign="top">Fructose-bisphosphate aldolase B</td>
</tr>
<tr>
<td align="left" valign="top">P04406</td>
<td align="left" valign="top">GAPDH</td>
<td align="left" valign="top">Glyceraldehyde-3-phosphate dehydrogenase</td>
</tr>
<tr>
<td align="left" valign="top">P04075</td>
<td align="left" valign="top">ALDOA</td>
<td align="left" valign="top">Fructose-bisphosphate aldolase A</td>
</tr>
<tr>
<td align="left" valign="top">P02760</td>
<td align="left" valign="top">AMBP</td>
<td align="left" valign="top">Alpha-1-microglobulin</td>
</tr>
<tr>
<td align="left" valign="top">P02748</td>
<td align="left" valign="top">C9</td>
<td align="left" valign="top">Complement component C9</td>
</tr>
<tr>
<td align="left" valign="top">P02743</td>
<td align="left" valign="top">APCS</td>
<td align="left" valign="top">Serum amyloid P-component</td>
</tr>
<tr>
<td align="left" valign="top">P01857; P01859; P0DOX5</td>
<td align="left" valign="top">IGHG2</td>
<td align="left" valign="top">Immunoglobulin heavy constant gamma 2</td>
</tr>
<tr>
<td align="left" valign="top">P01857; P01860; P01861; P0DOX5</td>
<td align="left" valign="top">IGHG1</td>
<td align="left" valign="top">Immunoglobulin heavy constant gamma 1</td>
</tr>
<tr>
<td align="left" valign="top">P01834; P0DOX7</td>
<td align="left" valign="top">IGKC</td>
<td align="left" valign="top">Immunoglobulin kappa constant</td>
</tr>
<tr>
<td align="left" valign="top">P01766</td>
<td align="left" valign="top">IGHV3-13</td>
<td align="left" valign="top">Immunoglobulin heavy variable 3&#x2013;13</td>
</tr>
<tr>
<td align="left" valign="top">P01742</td>
<td align="left" valign="top">IGHV1-69</td>
<td align="left" valign="top">Immunoglobulin heavy variable 1&#x2013;69</td>
</tr>
<tr>
<td align="left" valign="top">P01714</td>
<td align="left" valign="top">IGLV3-19</td>
<td align="left" valign="top">Immunoglobulin lambda variable 3&#x2013;19</td>
</tr>
<tr>
<td align="left" valign="top">O75636</td>
<td align="left" valign="top">FCN3</td>
<td align="left" valign="top">Ficolin-3</td>
</tr>
<tr>
<td align="left" valign="top">P0CG04; P0DOY2; P0DOY3; A0M8Q6; P0CF74; B9A064; P0DOX8</td>
<td align="left" valign="top">IGLL5</td>
<td align="left" valign="top">Immunoglobulin lambda-like polypeptide 5</td>
</tr>
<tr>
<td align="left" valign="top">P01599; A0A0C4DH72</td>
<td align="left" valign="top">IGKV1-6</td>
<td align="left" valign="top">Immunoglobulin kappa variable 1&#x2013;6</td>
</tr>
<tr>
<td align="left" valign="top">P01814; A0A0C4DH43</td>
<td align="left" valign="top">IGHV2-70D</td>
<td align="left" valign="top">Immunoglobulin heavy variable 2-70D</td>
</tr>
<tr>
<td align="left" valign="top">A0A0B4J1X8</td>
<td align="left" valign="top">IGHV3-43</td>
<td align="left" valign="top">Immunoglobulin heavy variable 3&#x2013;43</td>
</tr>
<tr>
<td align="left" valign="top">P01615; A0A075B6P5</td>
<td align="left" valign="top">IGKV2-28; IGKV2D-28</td>
<td align="left" valign="top">Immunoglobulin kappa variable 2&#x2013;28</td>
</tr>
<tr>
<td align="left" valign="top">A0A0B4J1V2</td>
<td align="left" valign="top">IGHV2-26</td>
<td align="left" valign="top">Immunoglobulin heavy variable 2&#x2013;26</td>
</tr>
<tr>
<td align="left" valign="top" colspan="3">Higher in BEET trial</td>
</tr>
<tr>
<td align="left" valign="top">Q8NBJ4</td>
<td align="left" valign="top">GOLM1</td>
<td align="left" valign="top">Golgi membrane protein 1</td>
</tr>
<tr>
<td align="left" valign="top">Q7Z7M0</td>
<td align="left" valign="top">MEGF8</td>
<td align="left" valign="top">Multiple epidermal growth factor-like domains protein 8</td>
</tr>
<tr>
<td align="left" valign="top">Q7Z7G0</td>
<td align="left" valign="top">ABI3BP</td>
<td align="left" valign="top">Target of Nesh-SH3</td>
</tr>
<tr>
<td align="left" valign="top">Q15084</td>
<td align="left" valign="top">PDIA6</td>
<td align="left" valign="top">Protein disulfide-isomerase A6</td>
</tr>
<tr>
<td align="left" valign="top">Q13103</td>
<td align="left" valign="top">SPP2</td>
<td align="left" valign="top">Secreted phosphoprotein 24</td>
</tr>
<tr>
<td align="left" valign="top">Q05682</td>
<td align="left" valign="top">CALD1</td>
<td align="left" valign="top">Caldesmon</td>
</tr>
<tr>
<td align="left" valign="top">P54289</td>
<td align="left" valign="top">CACNA2D1</td>
<td align="left" valign="top">Voltage-dependent calcium channel subunit alpha-2/delta-1</td>
</tr>
<tr>
<td align="left" valign="top">P23528; Q9Y281</td>
<td align="left" valign="top">CFL1</td>
<td align="left" valign="top">Cofilin-1</td>
</tr>
<tr>
<td align="left" valign="top">P18065</td>
<td align="left" valign="top">IGFBP2</td>
<td align="left" valign="top">Insulin-like growth factor-binding protein 2</td>
</tr>
<tr>
<td align="left" valign="top">P16930</td>
<td align="left" valign="top">FAH</td>
<td align="left" valign="top">Fumarylacetoacetase</td>
</tr>
<tr>
<td align="left" valign="top">P13645</td>
<td align="left" valign="top">KRT10</td>
<td align="left" valign="top">Keratin, type I cytoskeletal 10</td>
</tr>
<tr>
<td align="left" valign="top">P13591</td>
<td align="left" valign="top">NCAM1</td>
<td align="left" valign="top">Neural cell adhesion molecule 1</td>
</tr>
<tr>
<td align="left" valign="top">P0DMV8; P0DMV9; P11142; P17066; P34931; P54652; P48741</td>
<td align="left" valign="top">HSPA8</td>
<td align="left" valign="top">Heat shock cognate 71&#x2009;kDa protein</td>
</tr>
<tr>
<td align="left" valign="top">P08758</td>
<td align="left" valign="top">ANXA5</td>
<td align="left" valign="top">Annexin A5</td>
</tr>
<tr>
<td align="left" valign="top">P05362</td>
<td align="left" valign="top">ICAM1</td>
<td align="left" valign="top">Intercellular adhesion molecule 1</td>
</tr>
<tr>
<td align="left" valign="top">P04070</td>
<td align="left" valign="top">PROC</td>
<td align="left" valign="top">Vitamin K-dependent protein C</td>
</tr>
<tr>
<td align="left" valign="top">P02765</td>
<td align="left" valign="top">AHSG</td>
<td align="left" valign="top">Alpha-2-HS-glycoprotein</td>
</tr>
<tr>
<td align="left" valign="top">P02753</td>
<td align="left" valign="top">RBP4</td>
<td align="left" valign="top">Retinol-binding protein 4</td>
</tr>
<tr>
<td align="left" valign="top">P02656</td>
<td align="left" valign="top">APOC3</td>
<td align="left" valign="top">Apolipoprotein C-III</td>
</tr>
<tr>
<td align="left" valign="top">P01614; A0A087WW87</td>
<td align="left" valign="top">IGKV2-40; IGKV2D-40</td>
<td align="left" valign="top">Immunoglobulin kappa variable 2&#x2013;40</td>
</tr>
<tr>
<td align="left" valign="top">O15031</td>
<td align="left" valign="top">PLXNB2</td>
<td align="left" valign="top">Plexin-B2</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig position="float" id="fig5">
<label>Figure 5</label>
<caption>
<p>Protein&#x2013;protein interaction networks and functional enrichments of <bold>(A)</bold> cluster 1 (45 proteins) that were lower and <bold>(B)</bold> cluster 2 (21 proteins) that were higher in the BEET compared to placebo trials.</p>
</caption>
<graphic xlink:href="fnut-11-1408804-g005.tif"/>
</fig>
</sec>
<sec sec-type="discussion" id="sec15">
<title>Discussion</title>
<p>This study employed a strong research design to investigate the effects of 2-weeks intake of a mixed beet-based supplement (212&#x2009;mg nitrates per day) on inflammation induced by a 2.25&#x2009;h cycling bout with 20 cyclists. A multi-omics approach was used, and this included a comprehensive targeted oxylipins panel and the measurement of several hundred proteins using untargeted proteomics. BEET supplementation significantly increased plasma NO<sub>3</sub><sup>&#x2212;</sup>&#x2009;+&#x2009;NO<sub>2</sub><sup>&#x2212;</sup> 1.6-fold after the 2-week supplementation period and 2.6-fold above placebo levels immediately after the cycling bout. The 2.25&#x2009;h cycling bout caused significant inflammation with a composite variable of 41 oxylipins rising 3.4-fold immediately post-exercise above baseline plasma levels. Plasma oxylipins were still elevated 1.5-fold at the 3&#x2009;h-post-exercise time point before falling to near baseline levels after 24&#x2009;h recovery. BEET supplementation did not reduce post-exercise plasma concentrations of pro-inflammatory oxylipins but did have a modest effect in elevating two anti-inflammatory EPA- and DHA-derived oxylipins (18-HEPE and 4-HDoHE). Two-way ANOVA revealed 66 proteins that were increased or decreased with BEET supplementation, and functional enrichment supported significant BEET-related reductions in inflammation-related proteins including proteins related to complement activation, the acute phase response, and immune cell adhesion, migration, and differentiation.</p>
<p>This is the first exercise-based human clinical trial to investigate the influence of BEET supplementation on inflammation using a human systems biology approach. Other similar studies used a few targeted outcomes, had widely disparate research designs, and generally reported null or minor effects of increased plasma NO<sub>3</sub><sup>&#x2212;</sup>&#x2009;+&#x2009;NO<sub>2</sub><sup>&#x2212;</sup> from nitrate supplementation on post-exercise inflammation biomarkers including cytokines (<xref ref-type="bibr" rid="ref8">8</xref>, <xref ref-type="bibr" rid="ref17 ref18 ref19">17&#x2013;19</xref>). In one study with 34 runners, beetroot juice versus placebo supplementation for 3&#x2009;days following a marathon race had no effect on muscle soreness, creatine kinase, interleukin (IL)-6, IL-8, tumor necrosis factor-&#x03B1; (TNF&#x03B1;), blood leukocyte cell counts, or C-reactive protein (CRP) (<xref ref-type="bibr" rid="ref19">19</xref>). The major limitation was that beetroot juice supplementation was restricted to the 3-day period after running the marathon race when most of the inflammation biomarkers were similar to pre-marathon levels.</p>
<p>Nearly all inflammation regulatory oxylipins generated in response to exercise stress come from PUFA substrates that are released from cell membranes and subsequently oxidized from CYP, LOX, and COX enzyme systems (<xref ref-type="bibr" rid="ref20">20</xref>). Oxylipin production during recovery from prolonged and intensive cycling is sensitive to nutritional interventions including carbohydrate and blueberry supplementation (<xref ref-type="bibr" rid="ref20 ref21 ref22 ref23 ref24">20&#x2013;24</xref>). Underlying mechanisms are still being explored but may include the influence of glucose and polyphenol metabolites on CYP, LOX, and COX enzyme activity and the subsequent generation of specific oxylipin subgroups (<xref ref-type="bibr" rid="ref21 ref22 ref23 ref24">21&#x2013;24</xref>). Nitric oxide in cell culture and rodent-based studies inhibits P450 and LOX enzymes through multiple pathways, and can inhibit or stimulate COX enzymes depending on the physiological context (<xref ref-type="bibr" rid="ref35">35</xref>, <xref ref-type="bibr" rid="ref36">36</xref>). Nitric oxide and oxylipins are viewed as interdependent signaling systems that help regulate inflammation, immune, and metabolic responses (<xref ref-type="bibr" rid="ref37">37</xref>). Human clinical trials focused on nitrate supplementation and inflammation regulation from nitric oxide and oxylipins, however, are lacking.</p>
<p>In our study, BEET supplementation had a modest effect in increasing post-exercise EPA-COX derived HEPE-18 and DHA-LOX derived 4-HDoHE but had no significant effects on the generation of pro-inflammatory linoleic acid (LA)-CYP, LA-LOX, or arachidonic (ARA)-CYP oxylipins. These results suggest that pro-inflammatory oxylipin generation after 2.25&#x2009;h intensive cycling is relatively unaffected by increases in plasma NO<sub>3</sub><sup>&#x2212;</sup>&#x2009;+&#x2009;NO<sub>2</sub><sup>&#x2212;</sup> with 2-weeks BEET intake. Whether or not higher and/or longer duration BEET or nitrate dosing may alter these results remains to be determined. In two previous studies, we showed that 14&#x2013;18&#x2009;days supplementation with 1 cup equivalent of blueberries had significant effects on post-exercise plasma oxylipin concentrations (<xref ref-type="bibr" rid="ref21">21</xref>, <xref ref-type="bibr" rid="ref23">23</xref>). In one of these studies, blueberry ingestion was linked to a sustained elevation in DHA- and EPA-derived anti-inflammatory oxylipins including 18-HEPE in response to a 90-min bout of unaccustomed exercise by untrained adults (<xref ref-type="bibr" rid="ref21">21</xref>). 18-HEPE is a precursor for resolvins that are specialized pro-resolving lipid mediators (SPM) with well-defined roles in inflammation resolution (<xref ref-type="bibr" rid="ref38">38</xref>). 4-HDoHE is a beneficial 5-LOX oxidation product from DHA. Limited data indicate that this oxylipin in cell culture exerts anti-oxidative and anti-inflammatory effects on brain and blood vessel tissues through nuclear factor erythroid 2&#x2013;related factor 2 (Nrf2) activation (<xref ref-type="bibr" rid="ref39">39</xref>, <xref ref-type="bibr" rid="ref40">40</xref>).</p>
<p>Previous studies using untargeted proteomics methods indicate that acute prolonged and intensive exercise bouts have a widespread effect on plasma concentrations of proteins involved in immune system and inflammation responses (<xref ref-type="bibr" rid="ref22">22</xref>, <xref ref-type="bibr" rid="ref25 ref26 ref27">25&#x2013;27</xref>, <xref ref-type="bibr" rid="ref41">41</xref>, <xref ref-type="bibr" rid="ref42">42</xref>). The use of untargeted proteomics in studies with a sports nutrition focus is an emerging research design approach (<xref ref-type="bibr" rid="ref22">22</xref>, <xref ref-type="bibr" rid="ref43">43</xref>). In a recent untargeted proteomics-based study, our research group showed that 4-weeks supplementation with the keto-carotenoid astaxanthin (8&#x2009;mg/day) countered post-exercise decreases in humoral immunity and plasma immunoglobulins in athletes engaging in a vigorous 2.25&#x2009;h running bout (<xref ref-type="bibr" rid="ref22">22</xref>). In the current study, untargeted proteomics revealed an extensive effect of BEET versus placebo supplementation on 66 proteins, with lower plasma levels for a cluster of 45 proteins and higher levels for a cluster of 21 proteins. Functional enrichment supported a significant reduction in exercise-induced complement activation and inflammatory and stimulus responses. Key inflammation-related proteins that were lower with BEET supplementation included complements C3, C5, and C9, properdin (a positive regulator of the alternate pathway of complement), ficolin-3 (innate immune activator through the lectin complement pathway), serum amyloids A1 and P (acute phase proteins), alpha-1-microglobulin (an inflammation biomarker with acute phase proteins), clusterin (diverse inflammation roles), fibulin-1 and fermitin family homolog 3 (both involved with cell adhesion, migration, and differentiation), hypoxia up-regulated protein 1 (heat shock protein), coronin-1C (plays an important role in immune cell motility and vesicle trafficking), peroxiredoxin-1 (anti-oxidant that can promote inflammation), peroxisome proliferator-activated receptor-delta (regulates cellular metabolic functions and can promote inflammation), reelin (pro-inflammatory and pro-thrombotic factor), and dipeptidyl peptidase 4 membrane form (regulator of T-cell proliferation and natural killer cell kappa B activation). The liver is the source of most complement and acute phase proteins, and complement activation after prolonged and intensive exercise is an acute phase response to physiological stress (<xref ref-type="bibr" rid="ref44">44</xref>). Nitric oxide is a pleiotropic and pervasive signaling molecule and influences inflammation in multiple ways including the suppression of immune cell growth, cytokine production, and platelet activation, and regulation of NF-&#x03BA;B activation (<xref ref-type="bibr" rid="ref45">45</xref>).</p>
<p><xref ref-type="table" rid="tab5">Table 5</xref> lists 14 immunoglobulin proteins that were lower with BEET versus placebo supplementation. Functional enrichment through STRING does not include immunoglobulins. Although human data are limited, emerging results from animal-based studies indicate an inverse relationship between nitric oxide and immunoglobulin production (<xref ref-type="bibr" rid="ref46 ref47 ref48">46&#x2013;48</xref>). Elevated nitric oxide may have multiple negative influences on B cell function. Nitric oxide generated from inflammatory monocytes, for example, can decrease B cell survival and hence antibody production (<xref ref-type="bibr" rid="ref47">47</xref>). Vaccine adjuvants are being developed to counter the negative effect of nitric oxide on antibody responses (<xref ref-type="bibr" rid="ref48">48</xref>). Our finding that BEET intake was associated with lower immunoglobulin proteins in cyclists during recovery from vigorous exercise was unexpected and needs to be confirmed in future studies and then evaluated for clinical significance.</p>
<p>BEET supplementation was linked to an increase in proteins involved with regulation of insulin like growth factors (IGFs) and symbiotic interactions. The IGF-axis mediates many of the physiological effects of growth hormone and is involved in the regulation of cell growth, proliferation, and survival (<xref ref-type="bibr" rid="ref49">49</xref>). IGF binding protein 2 (IGFBP2) modifies IGF-1 functions and this protein was elevated with BEET supplementation. Nitric oxide mediates some of the effects of IGF-1 on vasodilation, increased blood flow, and lowered blood pressure (<xref ref-type="bibr" rid="ref50">50</xref>). Other proteins with symbiotic interactions were elevated with BEET supplementation including neural cell adhesion molecule 1 (NCAM1 or CD56), heat shock cognate 71&#x2009;kDa protein (HSPA8), and annexin A5. These proteins contribute to many biological processes including cell growth and differentiation, signaling, protein homeostasis, and apoptosis (<xref ref-type="bibr" rid="ref51 ref52 ref53">51&#x2013;53</xref>). Alpha-2-HS-glycoprotein or fetuin-A is a multifunctional protein, has a complex involvement with inflammation depending on the physiological context, and can function as an anti-inflammatory acute phase protein (<xref ref-type="bibr" rid="ref54">54</xref>). Intercellular adhesion molecule 1 (ICAM-1) is an adhesion receptor and was also elevated with BEET supplementation. ICAM-1 regulates inflammatory responses by controlling leukocyte recruitment from the blood compartment to sites of inflammation and also is involved in epithelial injury-resolution responses (<xref ref-type="bibr" rid="ref55">55</xref>).</p>
<p>The strength of this study was the combination of a strong research design and multi-omics outcomes to determine if exercise-induced inflammation could be moderated with BEET supplementation. There are several research design features and limitations that should be considered when interpreting study results. This study included non-elite male and female cyclists who were generally middle-aged and cycled for 2&#x2009;h 15&#x2009;min at about 75% VO<sub>2max</sub>. Thus, the results of this study may not apply to younger elite endurance athletes who exercise at higher intensities. The research design included a 2-week supplementation period of BEET or placebo (two doses per day) with intake continued the day of the exercise challenge. Thus, the changes in protein biomarkers reported in this study could be related to both acute and chronic BEET intake. This research design element is consistent with the practice of many athletes who consume supplements both during training and on the day of competition. Plant-based supplements undergo a complex metabolic process involving the oral and gut microbiomes, metabolite formation from substrates, and subsequent biochemical effects on various enzyme systems including those related to inflammation. Our blood samples were collected in an overnight fasted state (pre- and post-supplementation). On the exercise challenge day, the blood collection was followed by the normal BEET dose and then the cycling bout. Thus, subjects had not consumed the BEET or placebo supplement since the prior day (midday) and most likely explains the low pre-exercise plasma NO<sub>3</sub><sup>&#x2212;</sup>&#x2009;+&#x2009;NO<sub>2</sub><sup>&#x2212;</sup> levels. The primary purpose of this study was to investigate the effects of BEET supplementation on exercise-induced inflammation. For this reason, participants exercised in an overnight fasted state to avoid the interactive effects of carbohydrate intake on inflammation. The BEET supplement included a moderate amount of nitrate from beets and fermented beets with caffeine, vitamin C, and other food components that may minimize risks from N-nitroso compounds. Beetroot powder also contains other phytochemicals that may have bioactive effects. We cannot rule out the potential synergistic effects of these other ingredients with beetroot on inflammation.</p>
</sec>
<sec sec-type="conclusions" id="sec16">
<title>Conclusion</title>
<p>This randomized crossover study used a 2.25&#x2009;h cycling bout to induce inflammation. Using double blind, placebo-controlled methods, 2-weeks intake of a BEET-based supplement with a moderate amount of nitrate (212&#x2009;mg/d) increased plasma levels of NO<sub>3</sub><sup>&#x2212;</sup>&#x2009;+&#x2009;NO<sub>2</sub><sup>&#x2212;</sup>. BEET supplementation did not counter exercise-induced increases in pro-inflammatory oxylipins but did increase post-exercise levels of two anti-inflammatory EPA- and DHA-derived oxylipins. The strongest effect of BEET supplementation was related to a significant decrease in a cluster of proteins involved in complement activation and inflammation. These data support that 2-weeks intake of a mixed beet-based supplement with morning and midday doses moderates protein biomarkers of exercise-induced inflammation in athletes. Carbohydrate and blueberry ingestion also mitigate post-exercise inflammation, an effect that requires more investigation for biological and clinical significance, but is generally interpreted as beneficial to the athlete over the long term (<xref ref-type="bibr" rid="ref21">21</xref>, <xref ref-type="bibr" rid="ref23">23</xref>, <xref ref-type="bibr" rid="ref24">24</xref>, <xref ref-type="bibr" rid="ref29">29</xref>). This study did not focus on testing different formulations or dosing approaches. Future research can establish whether higher beet-nitrate intake with various types of adjuvants over a longer time period can amplify the anti-inflammatory effects, especially on pro-inflammatory oxylipins.</p>
</sec>
<sec sec-type="data-availability" id="sec17">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="sec" rid="sec23">Supplementary material</xref>.</p>
</sec>
<sec sec-type="ethics-statement" id="sec18">
<title>Ethics statement</title>
<p>The studies involving humans were approved by Appalachian State University Institutional Review Board, NIH. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p>
</sec>
<sec sec-type="author-contributions" id="sec19">
<title>Author contributions</title>
<p>DN: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing &#x2013; original draft, Writing &#x2013; review &#x0026; editing. CS: Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing &#x2013; review &#x0026; editing. JW: Formal analysis, Investigation, Methodology, Writing &#x2013; review &#x0026; editing. FM: Data curation, Formal analysis, Methodology, Writing &#x2013; review &#x0026; editing. PS: Data curation, Formal analysis, Investigation, Methodology, Writing &#x2013; review &#x0026; editing. AO: Data curation, Formal analysis, Investigation, Writing &#x2013; review &#x0026; editing. QZ: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Supervision, Writing &#x2013; review &#x0026; editing.</p>
</sec>
</body>
<back>
<sec sec-type="funding-information" id="sec20">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by Standard Process, Palmyra, Wisconsin, USA. The funder had no role in the study design, data collection, analysis and interpretation, the preparation of the manuscript, or in the decision to submit the article for publication.</p>
</sec>
<ack>
<p>The authors thank Standard Process for providing the supplements for this study.</p>
</ack>
<sec sec-type="COI-statement" id="sec21">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p>
</sec>
<sec sec-type="disclaimer" id="sec22">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec23">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fnut.2024.1408804/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fnut.2024.1408804/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Table_1.XLSX" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
<supplementary-material xlink:href="Table_2.XLSX" id="SM2" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<fn-group>
<fn id="fn0001">
<p>
<sup>1</sup>
<ext-link xlink:href="https://string-db.org/" ext-link-type="uri">https://string-db.org/</ext-link>
</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="ref1">
<label>1.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Babateen</surname> <given-names>AM</given-names></name> <name><surname>Fornelli</surname> <given-names>G</given-names></name> <name><surname>Donini</surname> <given-names>LM</given-names></name> <name><surname>Mathers</surname> <given-names>JC</given-names></name> <name><surname>Siervo</surname> <given-names>M</given-names></name></person-group>. <article-title>Assessment of dietary nitrate intake in humans: a systematic review</article-title>. <source>Am J Clin Nutr</source>. (<year>2018</year>) <volume>108</volume>:<fpage>878</fpage>&#x2013;<lpage>88</lpage>. doi: <pub-id pub-id-type="doi">10.1093/ajcn/nqy108</pub-id>, PMID: <pub-id pub-id-type="pmid">30321271</pub-id></citation>
</ref>
<ref id="ref2">
<label>2.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lundberg</surname> <given-names>JO</given-names></name> <name><surname>Weitzberg</surname> <given-names>E</given-names></name> <name><surname>Gladwin</surname> <given-names>MT</given-names></name></person-group>. <article-title>The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics</article-title>. <source>Nat Rev Drug Discov</source>. (<year>2008</year>) <volume>7</volume>:<fpage>156</fpage>&#x2013;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrd2466</pub-id></citation>
</ref>
<ref id="ref3">
<label>3.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kapil</surname> <given-names>V</given-names></name> <name><surname>Khambata</surname> <given-names>RS</given-names></name> <name><surname>Jones</surname> <given-names>DA</given-names></name> <name><surname>Rathod</surname> <given-names>K</given-names></name> <name><surname>Primus</surname> <given-names>C</given-names></name> <name><surname>Massimo</surname> <given-names>G</given-names></name> <etal/></person-group>. <article-title>The noncanonical pathway for in vivo nitric oxide generation: the nitrate-nitrite-nitric oxide pathway</article-title>. <source>Pharmacol Rev</source>. (<year>2020</year>) <volume>72</volume>:<fpage>692</fpage>&#x2013;<lpage>766</lpage>. doi: <pub-id pub-id-type="doi">10.1124/pr.120.019240</pub-id></citation>
</ref>
<ref id="ref4">
<label>4.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raubenheimer</surname> <given-names>K</given-names></name> <name><surname>Bondonno</surname> <given-names>C</given-names></name> <name><surname>Blekkenhorst</surname> <given-names>L</given-names></name> <name><surname>Wagner</surname> <given-names>K-H</given-names></name> <name><surname>Peake</surname> <given-names>JM</given-names></name> <name><surname>Neubauer</surname> <given-names>O</given-names></name></person-group>. <article-title>Effects of dietary nitrate on inflammation and immune function, and implications for cardiovascular health</article-title>. <source>Nutr Rev</source>. (<year>2019</year>) <volume>77</volume>:<fpage>584</fpage>&#x2013;<lpage>99</lpage>. doi: <pub-id pub-id-type="doi">10.1093/nutrit/nuz025</pub-id>, PMID: <pub-id pub-id-type="pmid">31150091</pub-id></citation>
</ref>
<ref id="ref5">
<label>5.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lorenzo Calvo</surname> <given-names>J</given-names></name> <name><surname>Alorda-Capo</surname> <given-names>F</given-names></name> <name><surname>Pareja-Galeano</surname> <given-names>H</given-names></name> <name><surname>Jim&#x00E9;nez</surname> <given-names>SL</given-names></name></person-group>. <article-title>Influence of nitrate supplementation on endurance cyclic sports performance: a systematic review</article-title>. <source>Nutrients</source>. (<year>2020</year>) <volume>12</volume>:<fpage>1796</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu12061796</pub-id>, PMID: <pub-id pub-id-type="pmid">32560317</pub-id></citation>
</ref>
<ref id="ref6">
<label>6.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname> <given-names>NF</given-names></name> <name><surname>Leveritt</surname> <given-names>MD</given-names></name> <name><surname>Pavey</surname> <given-names>TG</given-names></name></person-group>. <article-title>The effect of dietary nitrate supplementation on endurance exercise performance in healthy adults: a systematic review and meta-analysis</article-title>. <source>Sports Med</source>. (<year>2017</year>) <volume>47</volume>:<fpage>735</fpage>&#x2013;<lpage>56</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40279-016-0617-7</pub-id>, PMID: <pub-id pub-id-type="pmid">27600147</pub-id></citation>
</ref>
<ref id="ref7">
<label>7.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Senefeld</surname> <given-names>JW</given-names></name> <name><surname>Wiggins</surname> <given-names>CC</given-names></name> <name><surname>Regimbal</surname> <given-names>RJ</given-names></name> <name><surname>Dominelli</surname> <given-names>PB</given-names></name> <name><surname>Baker</surname> <given-names>SE</given-names></name> <name><surname>Joyner</surname> <given-names>MJ</given-names></name></person-group>. <article-title>Ergogenic effect of nitrate supplementation: a systematic review and meta-analysis</article-title>. <source>Med Sci Sports Exerc</source>. (<year>2020</year>) <volume>52</volume>:<fpage>2250</fpage>&#x2013;<lpage>61</lpage>. doi: <pub-id pub-id-type="doi">10.1249/MSS.0000000000002363</pub-id>, PMID: <pub-id pub-id-type="pmid">32936597</pub-id></citation>
</ref>
<ref id="ref8">
<label>8.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gamonales</surname> <given-names>JM</given-names></name> <name><surname>Rojas-Valverde</surname> <given-names>D</given-names></name> <name><surname>Mu&#x00F1;oz-Jim&#x00E9;nez</surname> <given-names>J</given-names></name> <name><surname>Serrano-Moreno</surname> <given-names>W</given-names></name> <name><surname>Ib&#x00E1;&#x00F1;ez</surname> <given-names>SJ</given-names></name></person-group>. <article-title>Effectiveness of nitrate intake on recovery from exercise-related fatigue: a systematic review</article-title>. <source>Int J Environ Res Public Health</source>. (<year>2022</year>) <volume>19</volume>:<fpage>12021</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijerph191912021</pub-id>, PMID: <pub-id pub-id-type="pmid">36231323</pub-id></citation>
</ref>
<ref id="ref9">
<label>9.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hogwood</surname> <given-names>AC</given-names></name> <name><surname>Anderson</surname> <given-names>KC</given-names></name> <name><surname>Ortiz de Zevallos</surname> <given-names>J</given-names></name> <name><surname>Paterson</surname> <given-names>C</given-names></name> <name><surname>Weltman</surname> <given-names>A</given-names></name> <name><surname>Allen</surname> <given-names>JD</given-names></name></person-group>. <article-title>Limited effects of inorganic nitrate supplementation on exercise training responses: a systematic review and meta-analysis</article-title>. <source>Sports Med Open</source>. (<year>2023</year>) <volume>9</volume>:<fpage>84</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40798-023-00632-1</pub-id>, PMID: <pub-id pub-id-type="pmid">37697072</pub-id></citation>
</ref>
<ref id="ref10">
<label>10.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berends</surname> <given-names>JE</given-names></name> <name><surname>van den Berg</surname> <given-names>LMM</given-names></name> <name><surname>Guggeis</surname> <given-names>MA</given-names></name> <name><surname>Henckens</surname> <given-names>NFT</given-names></name> <name><surname>Hossein</surname> <given-names>IJ</given-names></name> <name><surname>de Joode</surname> <given-names>MEJR</given-names></name> <etal/></person-group>. <article-title>Consumption of nitrate-rich beetroot juice with or without vitamin C supplementation increases the excretion of urinary nitrate, nitrite, and n-nitroso compounds in humans</article-title>. <source>Int J Mol Sci</source>. (<year>2019</year>) <volume>20</volume>:<fpage>2277</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms20092277</pub-id>, PMID: <pub-id pub-id-type="pmid">31072023</pub-id></citation>
</ref>
<ref id="ref11">
<label>11.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Said Abasse</surname> <given-names>K</given-names></name> <name><surname>Essien</surname> <given-names>EE</given-names></name> <name><surname>Abbas</surname> <given-names>M</given-names></name> <name><surname>Yu</surname> <given-names>X</given-names></name> <name><surname>Xie</surname> <given-names>W</given-names></name> <name><surname>Sun</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Association between dietary nitrate, nitrite intake, and site-specific cancer risk: a systematic review and meta-analysis</article-title>. <source>Nutrients</source>. (<year>2022</year>) <volume>14</volume>:<fpage>666</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu14030666</pub-id>, PMID: <pub-id pub-id-type="pmid">35277025</pub-id></citation>
</ref>
<ref id="ref12">
<label>12.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poortmans</surname> <given-names>JR</given-names></name> <name><surname>Gualano</surname> <given-names>B</given-names></name> <name><surname>Carpentier</surname> <given-names>A</given-names></name></person-group>. <article-title>Nitrate supplementation and human exercise performance: too much of a good thing?</article-title> <source>Curr Opin Clin Nutr Metab Care</source>. (<year>2015</year>) <volume>18</volume>:<fpage>1</fpage>&#x2013;<lpage>604</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MCO.0000000000000222</pub-id></citation>
</ref>
<ref id="ref13">
<label>13.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zamani</surname> <given-names>H</given-names></name> <name><surname>de Joode</surname> <given-names>MEJR</given-names></name> <name><surname>Hossein</surname> <given-names>IJ</given-names></name> <name><surname>Henckens</surname> <given-names>NFT</given-names></name> <name><surname>Guggeis</surname> <given-names>MA</given-names></name> <name><surname>Berends</surname> <given-names>JE</given-names></name> <etal/></person-group>. <article-title>The benefits and risks of beetroot juice consumption: a systematic review</article-title>. <source>Crit Rev Food Sci Nutr</source>. (<year>2021</year>) <volume>61</volume>:<fpage>788</fpage>&#x2013;<lpage>804</lpage>. doi: <pub-id pub-id-type="doi">10.1080/10408398.2020.1746629</pub-id></citation>
</ref>
<ref id="ref14">
<label>14.</label>
<citation citation-type="other"><person-group person-group-type="author"><collab id="coll1">Inchem</collab></person-group>. Nitrate (JECFA food additives series 50). (<year>2003</year>). Available at: <ext-link xlink:href="https://inchem.org/documents/jecfa/jecmono/v50je06.htm" ext-link-type="uri">https://inchem.org/documents/jecfa/jecmono/v50je06.htm</ext-link> (Accessed March 25, 2024).</citation>
</ref>
<ref id="ref15">
<label>15.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pinaffi-Langley</surname> <given-names>ACDC</given-names></name> <name><surname>Dajani</surname> <given-names>RM</given-names></name> <name><surname>Prater</surname> <given-names>MC</given-names></name> <name><surname>HVM</surname> <given-names>N</given-names></name> <name><surname>Vrancken</surname> <given-names>K</given-names></name> <name><surname>Hays</surname> <given-names>FA</given-names></name> <etal/></person-group>. <article-title>Dietary nitrate from plant foods: a conditionally essential nutrient for cardiovascular health</article-title>. <source>Adv Nutr</source>. (<year>2024</year>) <volume>15</volume>:<fpage>100158</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.advnut.2023.100158</pub-id>, PMID: <pub-id pub-id-type="pmid">38008359</pub-id></citation>
</ref>
<ref id="ref16">
<label>16.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ferrada-Contreras</surname> <given-names>E</given-names></name> <name><surname>Bonomini-Gnutzmann</surname> <given-names>R</given-names></name> <name><surname>Jorquera-Aguilera</surname> <given-names>C</given-names></name> <name><surname>MacmiIlan Kuthe</surname> <given-names>N</given-names></name> <name><surname>Pe&#x00F1;a-Jorquera</surname> <given-names>H</given-names></name> <name><surname>Rodr&#x00ED;guez-Rodr&#x00ED;guez</surname> <given-names>F</given-names></name></person-group>. <article-title>Does co-supplementation with beetroot juice and other nutritional supplements positively impact sports performance?: a systematic review</article-title>. <source>Nutrients</source>. (<year>2023</year>) <volume>15</volume>:<fpage>4838</fpage>. doi: <pub-id pub-id-type="doi">10.3390/nu15224838</pub-id>, PMID: <pub-id pub-id-type="pmid">38004231</pub-id></citation>
</ref>
<ref id="ref17">
<label>17.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname> <given-names>L</given-names></name> <name><surname>Bailey</surname> <given-names>SJ</given-names></name> <name><surname>Rowland</surname> <given-names>SN</given-names></name> <name><surname>Alsharif</surname> <given-names>N</given-names></name> <name><surname>Shannon</surname> <given-names>OM</given-names></name> <name><surname>Clifford</surname> <given-names>T</given-names></name></person-group>. <article-title>The effect of nitrate-rich beetroot juice on markers of exercise-induced muscle damage: a systematic review and meta-analysis of human intervention trials</article-title>. <source>J Diet Suppl</source>. (<year>2022</year>) <volume>19</volume>:<fpage>749</fpage>&#x2013;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1080/19390211.2021.1939472</pub-id>, PMID: <pub-id pub-id-type="pmid">34151694</pub-id></citation>
</ref>
<ref id="ref18">
<label>18.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rojano-Ortega</surname> <given-names>D</given-names></name> <name><surname>Pe&#x00F1;a Amaro</surname> <given-names>J</given-names></name> <name><surname>Berral-Aguilar</surname> <given-names>AJ</given-names></name> <name><surname>Berral-de la Rosa</surname> <given-names>FJ</given-names></name></person-group>. <article-title>Effects of beetroot supplementation on recovery after exercise-induced muscle damage: a systematic review. Sports</article-title>. <source>Health</source>. (<year>2022</year>) <volume>14</volume>:<fpage>556</fpage>&#x2013;<lpage>65</lpage>. doi: <pub-id pub-id-type="doi">10.1177/19417381211036412</pub-id>, PMID: <pub-id pub-id-type="pmid">34399653</pub-id></citation>
</ref>
<ref id="ref19">
<label>19.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clifford</surname> <given-names>T</given-names></name> <name><surname>Allerton</surname> <given-names>DM</given-names></name> <name><surname>Brown</surname> <given-names>MA</given-names></name> <name><surname>Harper</surname> <given-names>L</given-names></name> <name><surname>Horsburgh</surname> <given-names>S</given-names></name> <name><surname>Keane</surname> <given-names>KM</given-names></name> <etal/></person-group>. <article-title>Minimal muscle damage after a marathon and no influence of beetroot juice on inflammation and recovery</article-title>. <source>Appl Physiol Nutr Metab</source>. (<year>2017</year>) <volume>42</volume>:<fpage>263</fpage>&#x2013;<lpage>70</lpage>. doi: <pub-id pub-id-type="doi">10.1139/apnm-2016-0525</pub-id>, PMID: <pub-id pub-id-type="pmid">28165768</pub-id></citation>
</ref>
<ref id="ref20">
<label>20.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Signini</surname> <given-names>&#x00C9;F</given-names></name> <name><surname>Nieman</surname> <given-names>DC</given-names></name> <name><surname>Silva</surname> <given-names>CD</given-names></name> <name><surname>Sakaguchi</surname> <given-names>CA</given-names></name> <name><surname>Catai</surname> <given-names>AM</given-names></name></person-group>. <article-title>Oxylipin response to acute and chronic exercise: a systematic review</article-title>. <source>Meta</source>. (<year>2020</year>) <volume>10</volume>:<fpage>E264</fpage>. doi: <pub-id pub-id-type="doi">10.3390/metabo10060264</pub-id>, PMID: <pub-id pub-id-type="pmid">32630487</pub-id></citation>
</ref>
<ref id="ref21">
<label>21.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieman</surname> <given-names>DC</given-names></name> <name><surname>Sakaguchi</surname> <given-names>CA</given-names></name> <name><surname>Omar</surname> <given-names>AM</given-names></name> <name><surname>Davis</surname> <given-names>KL</given-names></name> <name><surname>Shaffner</surname> <given-names>CE</given-names></name> <name><surname>Strauch</surname> <given-names>RC</given-names></name> <etal/></person-group>. <article-title>Blueberry intake elevates post-exercise anti-inflammatory oxylipins: a randomized trial</article-title>. <source>Sci Rep</source>. (<year>2023</year>) <volume>13</volume>:<fpage>11976</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-023-39269-1</pub-id>, PMID: <pub-id pub-id-type="pmid">37488250</pub-id></citation>
</ref>
<ref id="ref22">
<label>22.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieman</surname> <given-names>DC</given-names></name> <name><surname>Woo</surname> <given-names>J</given-names></name> <name><surname>Sakaguchi</surname> <given-names>CA</given-names></name> <name><surname>Omar</surname> <given-names>AM</given-names></name> <name><surname>Tang</surname> <given-names>Y</given-names></name> <name><surname>Davis</surname> <given-names>K</given-names></name> <etal/></person-group>. <article-title>Astaxanthin supplementation counters exercise-induced decreases in immune-related plasma proteins</article-title>. <source>Front Nutr</source>. (<year>2023</year>) <volume>10</volume>:<fpage>1143385</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnut.2023.1143385</pub-id>, PMID: <pub-id pub-id-type="pmid">37025615</pub-id></citation>
</ref>
<ref id="ref23">
<label>23.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieman</surname> <given-names>DC</given-names></name> <name><surname>Gillitt</surname> <given-names>ND</given-names></name> <name><surname>Chen</surname> <given-names>G-Y</given-names></name> <name><surname>Zhang</surname> <given-names>Q</given-names></name> <name><surname>Sha</surname> <given-names>W</given-names></name> <name><surname>Kay</surname> <given-names>CD</given-names></name> <etal/></person-group>. <article-title>Blueberry and/or banana consumption mitigate arachidonic, cytochrome P450 oxylipin generation during recovery from 75-km cycling: a randomized trial</article-title>. <source>Front Nutr</source>. (<year>2020</year>) <volume>7</volume>:<fpage>121</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnut.2020.00121</pub-id>, PMID: <pub-id pub-id-type="pmid">32850939</pub-id></citation>
</ref>
<ref id="ref24">
<label>24.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieman</surname> <given-names>DC</given-names></name> <name><surname>Gillitt</surname> <given-names>ND</given-names></name> <name><surname>Chen</surname> <given-names>G-Y</given-names></name> <name><surname>Zhang</surname> <given-names>Q</given-names></name> <name><surname>Sakaguchi</surname> <given-names>CA</given-names></name> <name><surname>Stephan</surname> <given-names>EH</given-names></name></person-group>. <article-title>Carbohydrate intake attenuates post-exercise plasma levels of cytochrome P450-generated oxylipins</article-title>. <source>PLoS One</source>. (<year>2019</year>) <volume>14</volume>:<fpage>e0213676</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0213676</pub-id>, PMID: <pub-id pub-id-type="pmid">30883596</pub-id></citation>
</ref>
<ref id="ref25">
<label>25.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieman</surname> <given-names>DC</given-names></name> <name><surname>Groen</surname> <given-names>AJ</given-names></name> <name><surname>Pugachev</surname> <given-names>A</given-names></name> <name><surname>Vacca</surname> <given-names>G</given-names></name></person-group>. <article-title>Detection of functional overreaching in endurance athletes using proteomics</article-title>. <source>Proteomes</source>. (<year>2018</year>) <volume>6</volume>:<fpage>33</fpage>. doi: <pub-id pub-id-type="doi">10.3390/proteomes6030033</pub-id>, PMID: <pub-id pub-id-type="pmid">30200480</pub-id></citation>
</ref>
<ref id="ref26">
<label>26.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieman</surname> <given-names>DC</given-names></name> <name><surname>Groen</surname> <given-names>AJ</given-names></name> <name><surname>Pugachev</surname> <given-names>A</given-names></name> <name><surname>Simonson</surname> <given-names>AJ</given-names></name> <name><surname>Polley</surname> <given-names>K</given-names></name> <name><surname>James</surname> <given-names>K</given-names></name> <etal/></person-group>. <article-title>Proteomics-based detection of immune dysfunction in an elite adventure athlete trekking across the Antarctica</article-title>. <source>Proteomes</source>. (<year>2020</year>) <volume>8</volume>:<fpage>4</fpage>. doi: <pub-id pub-id-type="doi">10.3390/proteomes8010004</pub-id></citation>
</ref>
<ref id="ref27">
<label>27.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merritt</surname> <given-names>EK</given-names></name> <name><surname>Nieman</surname> <given-names>DC</given-names></name> <name><surname>Toone</surname> <given-names>BR</given-names></name> <name><surname>Groen</surname> <given-names>A</given-names></name> <name><surname>Pugachev</surname> <given-names>A</given-names></name></person-group>. <article-title>Proteomic markers of non-functional overreaching during the race across America (RAAM): a case study</article-title>. <source>Front Physiol</source>. (<year>2019</year>) <volume>10</volume>:<fpage>1410</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fphys.2019.01410</pub-id>, PMID: <pub-id pub-id-type="pmid">31798466</pub-id></citation>
</ref>
<ref id="ref28">
<label>28.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieman</surname> <given-names>DC</given-names></name> <name><surname>Sakaguchi</surname> <given-names>CA</given-names></name> <name><surname>Pelleigrini</surname> <given-names>M</given-names></name> <name><surname>Thompson</surname> <given-names>MJ</given-names></name> <name><surname>Sumner</surname> <given-names>S</given-names></name> <name><surname>Zhang</surname> <given-names>Q</given-names></name></person-group>. <article-title>Healthy lifestyle linked to innate immunity and lipoprotein metabolism: a cross-sectional comparison using untargeted proteomics</article-title>. <source>Sci Rep</source>. (<year>2023</year>) <volume>13</volume>:<fpage>16728</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-023-44068-9</pub-id>, PMID: <pub-id pub-id-type="pmid">37794065</pub-id></citation>
</ref>
<ref id="ref29">
<label>29.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieman</surname> <given-names>DC</given-names></name> <name><surname>Lila</surname> <given-names>MA</given-names></name> <name><surname>Gillitt</surname> <given-names>ND</given-names></name></person-group>. <article-title>Immunometabolism: a multi-omics approach to interpreting the influence of exercise and diet on the immune system</article-title>. <source>Annu Rev Food Sci Technol</source>. (<year>2019</year>) <volume>10</volume>:<fpage>341</fpage>&#x2013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-food-032818-121316</pub-id>, PMID: <pub-id pub-id-type="pmid">30633566</pub-id></citation>
</ref>
<ref id="ref30">
<label>30.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname> <given-names>LL</given-names></name> <name><surname>Brunetz</surname> <given-names>MH</given-names></name> <name><surname>Chenier</surname> <given-names>TC</given-names></name> <name><surname>McCammon</surname> <given-names>MR</given-names></name> <name><surname>Houmard</surname> <given-names>JA</given-names></name> <name><surname>Franklin</surname> <given-names>ME</given-names></name> <etal/></person-group>. <article-title>The effects of static and ballistic stretching on delayed onset muscle soreness and creatine kinase</article-title>. <source>Res Q Exerc Sport</source>. (<year>1993</year>) <volume>64</volume>:<fpage>103</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1080/02701367.1993.10608784</pub-id>, PMID: <pub-id pub-id-type="pmid">8451526</pub-id></citation>
</ref>
<ref id="ref31">
<label>31.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>G-Y</given-names></name> <name><surname>Zhang</surname> <given-names>Q</given-names></name></person-group>. <article-title>Comprehensive analysis of oxylipins in human plasma using reversed-phase liquid chromatography-triple quadrupole mass spectrometry with heatmap-assisted selection of transitions</article-title>. <source>Anal Bioanal Chem</source>. (<year>2019</year>) <volume>411</volume>:<fpage>367</fpage>&#x2013;<lpage>85</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00216-018-1446-3</pub-id>, PMID: <pub-id pub-id-type="pmid">30406832</pub-id></citation>
</ref>
<ref id="ref32">
<label>32.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname> <given-names>J</given-names></name> <name><surname>Zhang</surname> <given-names>Q</given-names></name></person-group>. <article-title>A streamlined high-throughput plasma proteomics platform for clinical proteomics with improved proteome coverage, reproducibility, and robustness</article-title>. <source>J Am Soc Mass Spectrom</source>. (<year>2023</year>) <volume>34</volume>:<fpage>754</fpage>&#x2013;<lpage>62</lpage>. doi: <pub-id pub-id-type="doi">10.1021/jasms.3c00022</pub-id>, PMID: <pub-id pub-id-type="pmid">36975161</pub-id></citation>
</ref>
<ref id="ref33">
<label>33.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Demichev</surname> <given-names>V</given-names></name> <name><surname>Messner</surname> <given-names>CB</given-names></name> <name><surname>Vernardis</surname> <given-names>SI</given-names></name> <name><surname>Lilley</surname> <given-names>KS</given-names></name> <name><surname>Ralser</surname> <given-names>M</given-names></name></person-group>. <article-title>DIA-NN: neural networks and interference correction enable deep proteome coverage in high throughput</article-title>. <source>Nat Methods</source>. (<year>2020</year>) <volume>17</volume>:<fpage>41</fpage>&#x2013;<lpage>4</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41592-019-0638-x</pub-id>, PMID: <pub-id pub-id-type="pmid">31768060</pub-id></citation>
</ref>
<ref id="ref34">
<label>34.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geyer</surname> <given-names>PE</given-names></name> <name><surname>Arend</surname> <given-names>FM</given-names></name> <name><surname>Doll</surname> <given-names>S</given-names></name> <name><surname>Louiset</surname> <given-names>M-L</given-names></name> <name><surname>Virreira Winter</surname> <given-names>S</given-names></name> <name><surname>M&#x00FC;ller-Reif</surname> <given-names>JB</given-names></name> <etal/></person-group>. <article-title>High-resolution serum proteome trajectories in COVID-19 reveal patient-specific seroconversion</article-title>. <source>EMBO Mol Med</source>. (<year>2021</year>) <volume>13</volume>:<fpage>e14167</fpage>. doi: <pub-id pub-id-type="doi">10.15252/emmm.202114167</pub-id>, PMID: <pub-id pub-id-type="pmid">34232570</pub-id></citation>
</ref>
<ref id="ref35">
<label>35.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morgan</surname> <given-names>ET</given-names></name> <name><surname>Skubic</surname> <given-names>C</given-names></name> <name><surname>Lee</surname> <given-names>C-M</given-names></name> <name><surname>Cokan</surname> <given-names>KB</given-names></name> <name><surname>Rozman</surname> <given-names>D</given-names></name></person-group>. <article-title>Regulation of cytochrome P450 enzyme activity and expression by nitric oxide in the context of inflammatory disease</article-title>. <source>Drug Metab Rev</source>. (<year>2020</year>) <volume>52</volume>:<fpage>455</fpage>&#x2013;<lpage>71</lpage>. doi: <pub-id pub-id-type="doi">10.1080/03602532.2020.1817061</pub-id>, PMID: <pub-id pub-id-type="pmid">32898444</pub-id></citation>
</ref>
<ref id="ref36">
<label>36.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salvemini</surname> <given-names>D</given-names></name> <name><surname>Kim</surname> <given-names>SF</given-names></name> <name><surname>Mollace</surname> <given-names>V</given-names></name></person-group>. <article-title>Reciprocal regulation of the nitric oxide and cyclooxygenase pathway in pathophysiology: relevance and clinical implications</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>. (<year>2013</year>) <volume>304</volume>:<fpage>R473</fpage>&#x2013;<lpage>87</lpage>. doi: <pub-id pub-id-type="doi">10.1152/ajpregu.00355.2012</pub-id>, PMID: <pub-id pub-id-type="pmid">23389111</pub-id></citation>
</ref>
<ref id="ref37">
<label>37.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname> <given-names>PRS</given-names></name> <name><surname>Schopfer</surname> <given-names>FJ</given-names></name> <name><surname>O&#x2019;Donnell</surname> <given-names>VB</given-names></name> <name><surname>Freeman</surname> <given-names>BA</given-names></name></person-group>. <article-title>Convergence of nitric oxide and lipid signaling: anti-inflammatory nitro-fatty acids</article-title>. <source>Free Radic Biol Med</source>. (<year>2009</year>) <volume>46</volume>:<fpage>989</fpage>&#x2013;<lpage>1003</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2008.11.021</pub-id>, PMID: <pub-id pub-id-type="pmid">19200454</pub-id></citation>
</ref>
<ref id="ref38">
<label>38.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weylandt</surname> <given-names>KH</given-names></name> <name><surname>Chiu</surname> <given-names>C-Y</given-names></name> <name><surname>Gomolka</surname> <given-names>B</given-names></name> <name><surname>Waechter</surname> <given-names>SF</given-names></name> <name><surname>Wiedenmann</surname> <given-names>B</given-names></name></person-group>. <article-title>Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation</article-title>. <source>Prostaglandins Other Lipid Mediat</source>. (<year>2012</year>) <volume>97</volume>:<fpage>73</fpage>&#x2013;<lpage>82</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.prostaglandins.2012.01.005</pub-id>, PMID: <pub-id pub-id-type="pmid">22326554</pub-id></citation>
</ref>
<ref id="ref39">
<label>39.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishikado</surname> <given-names>A</given-names></name> <name><surname>Morino</surname> <given-names>K</given-names></name> <name><surname>Nishio</surname> <given-names>Y</given-names></name> <name><surname>Nakagawa</surname> <given-names>F</given-names></name> <name><surname>Mukose</surname> <given-names>A</given-names></name> <name><surname>Sono</surname> <given-names>Y</given-names></name> <etal/></person-group>. <article-title>4-Hydroxy hexenal derived from docosahexaenoic acid protects endothelial cells via Nrf2 activation</article-title>. <source>PLoS One</source>. (<year>2013</year>) <volume>8</volume>:<fpage>e69415</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0069415</pub-id>, PMID: <pub-id pub-id-type="pmid">23936010</pub-id></citation>
</ref>
<ref id="ref40">
<label>40.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname> <given-names>B</given-names></name> <name><surname>Li</surname> <given-names>R</given-names></name> <name><surname>Michael Greenlief</surname> <given-names>C</given-names></name> <name><surname>Fritsche</surname> <given-names>KL</given-names></name> <name><surname>Gu</surname> <given-names>Z</given-names></name> <name><surname>Cui</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>Unveiling anti-oxidative and anti-inflammatory effects of docosahexaenoic acid and its lipid peroxidation product on lipopolysaccharide-stimulated BV-2 microglial cells</article-title>. <source>J Neuroinflammation</source>. (<year>2018</year>) <volume>15</volume>:<fpage>202</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12974-018-1232-3</pub-id>, PMID: <pub-id pub-id-type="pmid">29986724</pub-id></citation>
</ref>
<ref id="ref41">
<label>41.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dalle Carbonare</surname> <given-names>L</given-names></name> <name><surname>Manfredi</surname> <given-names>M</given-names></name> <name><surname>Caviglia</surname> <given-names>G</given-names></name> <name><surname>Conte</surname> <given-names>E</given-names></name> <name><surname>Robotti</surname> <given-names>E</given-names></name> <name><surname>Marengo</surname> <given-names>E</given-names></name> <etal/></person-group>. <article-title>Can half-marathon affect overall health? The yin-yang of sport</article-title>. <source>J Proteomics</source>. (<year>2018</year>) <volume>170</volume>:<fpage>80</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jprot.2017.09.004</pub-id></citation>
</ref>
<ref id="ref42">
<label>42.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balfoussia</surname> <given-names>E</given-names></name> <name><surname>Skenderi</surname> <given-names>K</given-names></name> <name><surname>Tsironi</surname> <given-names>M</given-names></name> <name><surname>Anagnostopoulos</surname> <given-names>AK</given-names></name> <name><surname>Parthimos</surname> <given-names>N</given-names></name> <name><surname>Vougas</surname> <given-names>K</given-names></name> <etal/></person-group>. <article-title>A proteomic study of plasma protein changes under extreme physical stress</article-title>. <source>J Proteome</source>. (<year>2014</year>) <volume>98</volume>:<fpage>1</fpage>&#x2013;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jprot.2013.12.004</pub-id>, PMID: <pub-id pub-id-type="pmid">24345577</pub-id></citation>
</ref>
<ref id="ref43">
<label>43.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nieman</surname> <given-names>DC</given-names></name>
</person-group>. <article-title>Multiomics approach to precision sports nutrition: limits, challenges, and possibilities</article-title>. <source>Front Nutr</source>. (<year>2021</year>) <volume>8</volume>:<fpage>796360</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fnut.2021.796360</pub-id>, PMID: <pub-id pub-id-type="pmid">34970584</pub-id></citation>
</ref>
<ref id="ref44">
<label>44.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothschild-Rodriguez</surname> <given-names>D</given-names></name> <name><surname>Causer</surname> <given-names>AJ</given-names></name> <name><surname>Brown</surname> <given-names>FF</given-names></name> <name><surname>Collier-Bain</surname> <given-names>HD</given-names></name> <name><surname>Moore</surname> <given-names>S</given-names></name> <name><surname>Murray</surname> <given-names>J</given-names></name> <etal/></person-group>. <article-title>The effects of exercise on complement system proteins in humans: a systematic scoping review</article-title>. <source>Exerc Immunol Rev</source>. (<year>2022</year>) <volume>28</volume>:<fpage>1</fpage>&#x2013;<lpage>35</lpage>. PMID: <pub-id pub-id-type="pmid">35452398</pub-id></citation>
</ref>
<ref id="ref45">
<label>45.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname> <given-names>S</given-names></name> <name><surname>Yuan</surname> <given-names>Z</given-names></name> <name><surname>Huang</surname> <given-names>Y</given-names></name></person-group>. <article-title>The potential role of nitric oxide as a therapeutic agent against SARS-CoV-2 infection</article-title>. <source>Int J Mol Sci</source>. (<year>2023</year>) <volume>24</volume>:<fpage>17162</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms242417162</pub-id>, PMID: <pub-id pub-id-type="pmid">38138990</pub-id></citation>
</ref>
<ref id="ref46">
<label>46.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Darling</surname> <given-names>RJ</given-names></name> <name><surname>Senapati</surname> <given-names>S</given-names></name> <name><surname>Kelly</surname> <given-names>SM</given-names></name> <name><surname>Kohut</surname> <given-names>ML</given-names></name> <name><surname>Narasimhan</surname> <given-names>B</given-names></name> <name><surname>Wannemuehler</surname> <given-names>MJ</given-names></name></person-group>. <article-title>STING pathway stimulation results in a differentially activated innate immune phenotype associated with low nitric oxide and enhanced antibody titers in young and aged mice</article-title>. <source>Vaccine</source>. (<year>2019</year>) <volume>37</volume>:<fpage>2721</fpage>&#x2013;<lpage>30</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.004</pub-id>, PMID: <pub-id pub-id-type="pmid">30987850</pub-id></citation>
</ref>
<ref id="ref47">
<label>47.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sala</surname> <given-names>E</given-names></name> <name><surname>Kuka</surname> <given-names>M</given-names></name></person-group>. <article-title>The suppressive attitude of inflammatory monocytes in antiviral antibody responses</article-title>. <source>Viral Immunol</source>. (<year>2020</year>) <volume>33</volume>:<fpage>327</fpage>&#x2013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.1089/vim.2019.0132</pub-id>, PMID: <pub-id pub-id-type="pmid">32027238</pub-id></citation>
</ref>
<ref id="ref48">
<label>48.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Senapati</surname> <given-names>S</given-names></name> <name><surname>Darling</surname> <given-names>RJ</given-names></name> <name><surname>Loh</surname> <given-names>D</given-names></name> <name><surname>Schneider</surname> <given-names>IC</given-names></name> <name><surname>Wannemuehler</surname> <given-names>MJ</given-names></name> <name><surname>Narasimhan</surname> <given-names>B</given-names></name> <etal/></person-group>. <article-title>Pentablock copolymer micelle nanoadjuvants enhance cytosolic delivery of antigen and improve vaccine efficacy while inducing low inflammation</article-title>. <source>ACS Biomater Sci Eng</source>. (<year>2019</year>) <volume>5</volume>:<fpage>1332</fpage>&#x2013;<lpage>42</lpage>. doi: <pub-id pub-id-type="doi">10.1021/acsbiomaterials.8b01591</pub-id>, PMID: <pub-id pub-id-type="pmid">33405651</pub-id></citation>
</ref>
<ref id="ref49">
<label>49.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rajpathak</surname> <given-names>SN</given-names></name> <name><surname>Gunter</surname> <given-names>MJ</given-names></name> <name><surname>Wylie-Rosett</surname> <given-names>J</given-names></name> <name><surname>Ho</surname> <given-names>GYF</given-names></name> <name><surname>Kaplan</surname> <given-names>RC</given-names></name> <name><surname>Muzumdar</surname> <given-names>R</given-names></name> <etal/></person-group>. <article-title>The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes</article-title>. <source>Diabetes Metab Res Rev</source>. (<year>2009</year>) <volume>25</volume>:<fpage>3</fpage>&#x2013;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1002/dmrr.919</pub-id>, PMID: <pub-id pub-id-type="pmid">19145587</pub-id></citation>
</ref>
<ref id="ref50">
<label>50.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muniyappa</surname> <given-names>R</given-names></name> <name><surname>Walsh</surname> <given-names>MF</given-names></name> <name><surname>Rangi</surname> <given-names>JS</given-names></name> <name><surname>Zayas</surname> <given-names>RM</given-names></name> <name><surname>Standley</surname> <given-names>PR</given-names></name> <name><surname>Ram</surname> <given-names>JL</given-names></name> <etal/></person-group>. <article-title>Insulin like growth factor 1 increases vascular smooth muscle nitric oxide production</article-title>. <source>Life Sci</source>. (<year>1997</year>) <volume>61</volume>:<fpage>925</fpage>&#x2013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0024-3205(97)00594-8</pub-id>, PMID: <pub-id pub-id-type="pmid">9284085</pub-id></citation>
</ref>
<ref id="ref51">
<label>51.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rutishauser</surname> <given-names>U</given-names></name> <name><surname>Acheson</surname> <given-names>A</given-names></name> <name><surname>Hall</surname> <given-names>AK</given-names></name> <name><surname>Mann</surname> <given-names>DM</given-names></name> <name><surname>Sunshine</surname> <given-names>J</given-names></name></person-group>. <article-title>The neural cell adhesion molecule (NCAM) as a regulator of cell-cell interactions</article-title>. <source>Science</source>. (<year>1988</year>) <volume>240</volume>:<fpage>53</fpage>&#x2013;<lpage>7</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.3281256</pub-id></citation>
</ref>
<ref id="ref52">
<label>52.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dores-Silva</surname> <given-names>PR</given-names></name> <name><surname>Cauvi</surname> <given-names>DM</given-names></name> <name><surname>Coto</surname> <given-names>ALS</given-names></name> <name><surname>Silva</surname> <given-names>NSM</given-names></name> <name><surname>Borges</surname> <given-names>JC</given-names></name> <name><surname>De Maio</surname> <given-names>A</given-names></name></person-group>. <article-title>Human heat shock cognate protein (HSC70/HSPA8) interacts with negatively charged phospholipids by a different mechanism than other HSP70s and brings HSP90 into membranes</article-title>. <source>Cell Stress Chaperones</source>. (<year>2021</year>) <volume>26</volume>:<fpage>671</fpage>&#x2013;<lpage>84</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12192-021-01210-8</pub-id>, PMID: <pub-id pub-id-type="pmid">34003451</pub-id></citation>
</ref>
<ref id="ref53">
<label>53.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jing</surname> <given-names>J</given-names></name>
</person-group>. <article-title>The relevance, predictability, and utility of annexin A5 for human physiopathology</article-title>. <source>Int J Mol Sci</source>. (<year>2024</year>) <volume>25</volume>:<fpage>2865</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms25052865</pub-id>, PMID: <pub-id pub-id-type="pmid">38474114</pub-id></citation>
</ref>
<ref id="ref54">
<label>54.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dogru</surname> <given-names>T</given-names></name> <name><surname>Kirik</surname> <given-names>A</given-names></name> <name><surname>Gurel</surname> <given-names>H</given-names></name> <name><surname>Rizvi</surname> <given-names>AA</given-names></name> <name><surname>Rizzo</surname> <given-names>M</given-names></name> <name><surname>Sonmez</surname> <given-names>A</given-names></name></person-group>. <article-title>The evolving role of fetuin-a in nonalcoholic fatty liver disease: an overview from liver to the heart</article-title>. <source>Int J Mol Sci</source>. (<year>2021</year>) <volume>22</volume>:<fpage>6627</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms22126627</pub-id></citation>
</ref>
<ref id="ref55">
<label>55.</label>
<citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bui</surname> <given-names>TM</given-names></name> <name><surname>Wiesolek</surname> <given-names>HL</given-names></name> <name><surname>Sumagin</surname> <given-names>R</given-names></name></person-group>. <article-title>ICAM-1: a master regulator of cellular responses in inflammation, injury resolution, and tumorigenesis</article-title>. <source>J Leukoc Biol</source>. (<year>2020</year>) <volume>108</volume>:<fpage>787</fpage>&#x2013;<lpage>99</lpage>. doi: <pub-id pub-id-type="doi">10.1002/JLB.2MR0220-549R</pub-id>, PMID: <pub-id pub-id-type="pmid">32182390</pub-id></citation>
</ref>
</ref-list>
</back>
</article>